Therapeutic radiolabeled nanoparticles and methods of use thereof

JP2023548553A5Pending Publication Date: 2024-11-12THE GENERAL HOSPITAL CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527020
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-03
Filing Date
2021-11-03
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Traditional treatments for primary tumors often fail to target metastatic cells, leading to poor prognosis in patients with metastatic disease, as these cells are genetically and phenotypically distinct and can spread to new organs, necessitating treatments tailored to their unique properties.

Method used

Therapeutic radiolabeled nanoparticles comprising a polymeric coating, a covalently attached chelator, a radioactive label, and a nucleic acid molecule, specifically designed to target and inhibit metastatic cells, with a diameter of 10-30 nm and magnetic properties, allowing for imaging and treatment of metastatic lesions.

Benefits of technology

The nanoparticles effectively reduce cancer cell invasion and metastasis, enable precise imaging of metastatic tissues, and provide sensitive detection at low doses, facilitating early drug development and personalized treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein are therapeutic nanoparticles comprising a radiolabel, a chelator covalently attached to the therapeutic nanoparticle and the radiolabel, and a nucleic acid molecule covalently attached to the therapeutic nanoparticle. The therapeutic nanoparticles have a diameter of about 10 nanometers (nm) to about 30 nm, and the therapeutic nanoparticles are magnetic. Also provided are pharmaceutical compositions comprising these therapeutic nanoparticles. Also provided herein are methods for reducing cancer cell invasion or metastasis in a subject with cancer, and methods for treating metastatic cancer in lymph nodes in a subject, which require administering these therapeutic nanoparticles to the subject. Also provided herein are methods for detecting, diagnosing, and / or monitoring metastatic cancer tissue in a subject. Also provided herein are methods for preparing these therapeutic nanoparticles.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 109,298, filed November 3, 2020, the entire contents of which are incorporated herein by reference.

[0002] Federally sponsored research or development This invention was made with government support under Grant No. CA16346101 awarded by the National Cancer Institute of the National Institutes of Health. The government has certain rights in this invention.

[0003] The present disclosure relates to therapeutic radiolabeled nanoparticles comprising a polymer coating and a covalently attached inhibitory nucleic acid, compositions comprising these therapeutic nanoparticles, methods of using these therapeutic nanoparticles, and methods of preparing these therapeutic nanoparticles. [Background technology]

[0004] Traditional therapies targeting primary tumor cells often fail to affect metastatic cells and may actually promote metastasis. This explains the poor prognosis for patients diagnosed with metastatic disease, despite the favorable prognosis for patients with localized cancer in the same organ of origin (Steeg PS Nat. Rev. Cancer. 2016;16:201-218). For these reasons, there is a need for therapies that target the unique properties of metastatic tumor cells. These cells have the ability to escape from the primary tumor mass, migrate through the circulation, and colonize new vital organs during the metastatic process. Importantly, these cells are genetically and phenotypically distinct from the bulk cells of the tumor mass, generating metastatic lesions with divergent gene expression profiles from their respective primary tumors. Summary of the Invention

[0005] Certain aspects of the present disclosure relate to therapeutic nanoparticles comprising a radiolabel; a chelator covalently attached to the therapeutic nanoparticle and the radiolabel; and a nucleic acid molecule covalently attached to the therapeutic nanoparticle, wherein the therapeutic nanoparticle has a diameter of about 10 nanometers (nm) to about 30 nm, and the therapeutic nanoparticle is magnetic.

[0006] In some embodiments, the chelator is covalently attached to the therapeutic nanoparticle via a chemical moiety containing a secondary amine. In some embodiments, the chelator comprises 1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid (NODAGA). In some embodiments, the chelator comprises DOTA, DOTA-GA, p-SCN-Bn-DOTA, CB-TE2A, CB-TE1A1P, AAZTA, MeCOSar, p-SCN-Bn-NOTA, NOTA, HBED-CC, THP, MAS3, DFO, or any combination thereof. In some embodiments, the radiolabel comprises copper-64 (Cu-64). In some embodiments, the radiolabel comprises copper-67 (Cu-67), yttrium-90 (Y-90), terbium-161 (Tb-161), lutetium-177 (Lu-177), bismuth-231 (Bi-213), lead-212 (Pb-212), actinium-225 (Ac-225), zirconium-89 (Zr), or any combination thereof. In some embodiments, the nucleic acid molecule comprises at least one modified nucleotide. In some embodiments, at least one modified nucleotide is a locked nucleotide. In some embodiments, the nucleic acid molecule is an antagomir. In some embodiments, the antagomir inhibits microRNA-10b (miR-10b). In some embodiments, the nucleic acid molecule is covalently attached to the nanoparticle via a chemical moiety comprising a disulfide bond. In some embodiments, the therapeutic nanoparticle comprises an iron oxide core. In some embodiments, the nanoparticle further comprises a polymer coating. In some embodiments, the polymer coating comprises dextran.

[0007] In another aspect, the present disclosure relates to a pharmaceutical composition comprising any of the therapeutic nanoparticles disclosed herein. In some embodiments, the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier or diluent. In some embodiments, the pharmaceutical composition is formulated into a dosage form that is an injection, a tablet, a lyophilized powder, a suspension, or any combination thereof.

[0008] In another aspect, the present disclosure relates to a method for reducing cancer cell invasion or metastasis in a subject having cancer, comprising administering any of the therapeutic nanoparticles disclosed herein to the subject having cancer, wherein the therapeutic nanoparticles are administered in an amount sufficient to reduce cancer cell invasion or metastasis in the subject.

[0009] In some embodiments, the therapeutic nanoparticles are administered to the subject at a dose of less than about 0.014 mg / kg. In some embodiments, the metastasis of cancer cells is metastasis from a primary tumor to a lymph node in the subject, or metastasis from a lymph node to a secondary tissue in the subject. In some embodiments, the cancer cells are selected from the group consisting of breast cancer cells, colon cancer cells, kidney cancer cells, lung cancer cells, skin cancer cells, ovarian cancer cells, pancreatic cancer cells, prostate cancer cells, rectal cancer cells, gastric cancer cells, thyroid cancer cells, and uterine cancer cells. In some embodiments, the method further comprises imaging the subject's tissue to determine the location or number of cancer cells in the subject or the location of the therapeutic nanoparticles in the subject.

[0010] In another aspect, the present disclosure relates to a method of treating metastatic cancer in a lymph node of a subject, comprising administering any of the therapeutic nanoparticles disclosed herein to a lymph node of a subject having metastatic cancer, wherein the therapeutic nanoparticles are administered in an amount sufficient to treat the metastatic cancer in the lymph node of the subject.

[0011] In some embodiments, the metastatic cancer arises from a primary breast cancer. In some embodiments, the administering results in a reduction or stabilization of the size of the metastatic tumor, or a reduction in the rate of metastatic tumor growth in lymph nodes in the subject.

[0012] In another aspect, the present disclosure relates to a method for detecting, diagnosing, and / or monitoring metastatic cancer tissue in a subject, the method comprising administering to a subject having metastatic cancer tissue any of the therapeutic nanoparticles disclosed herein; and imaging the therapeutic nanoparticles, wherein the therapeutic nanoparticles are administered in an amount sufficient to image the therapeutic nanoparticles in the subject.

[0013] In some embodiments, the imaging is performed by magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), computed tomography (CT), or any combination thereof. In some embodiments, the therapeutic nanoparticles are administered to the subject in two or more doses. In some embodiments, the therapeutic nanoparticles are administered to the subject at least once a week. In some embodiments, the therapeutic nanoparticles are administered to the subject by intravenous, subcutaneous, intraarterial, intramuscular, or intraperitoneal administration. In some embodiments, the subject is further administered a chemotherapeutic agent.

[0014] In another aspect, the present disclosure provides a method for preparing any of the therapeutic nanoparticles disclosed herein, comprising: preparing magnetic nanoparticles; covalently attaching a nucleic acid molecule to the magnetic nanoparticles; covalently attaching a chelator to the magnetic nanoparticles by reacting the magnetic nanoparticles with a chelator at a ratio of about 40 chelator equivalents per magnetic nanoparticle; 64 Adding CuCl2 solution to the magnetic nanoparticles; and 64 The present invention relates to a method comprising purifying a mixture of CuCl2 solution and magnetic nanoparticles to obtain therapeutic nanoparticles.

[0015] In some embodiments, covalently attaching the chelator to the magnetic nanoparticles is performed at a temperature of about 0° C. to about 8° C. In some embodiments, the method comprises: 64 The method further includes heating the mixture of CuCl2 solution and magnetic nanoparticles at a temperature between about 40° C. and about 65° C. In some embodiments, the mixture is heated for between about 10 minutes and about 30 minutes.

[0016] The term "magnetic" is used to describe a composition that responds to a magnetic field. Non-limiting examples of magnetic compositions (e.g., any of the nanoparticle compositions described herein) can include materials that are paramagnetic, superparamagnetic, ferromagnetic, or diamagnetic. Non-limiting examples of magnetic compositions include metal oxides selected from the group of magnetite; ferrites (e.g., manganese, cobalt, and nickel ferrites); Fe(II) oxide; and hematite, and metal alloys thereof. Additional magnetic materials are described herein and known in the art.

[0017] The term "diamagnetic" is used to describe compositions that have a relative magnetic permeability that is less than or equal to 1 and are repelled by magnetic fields.

[0018] The term "paramagnetic" is used to describe a composition that develops a magnetic moment only in the presence of an externally applied magnetic field.

[0019] The terms "ferromagnetic" or "ferromagnetic" are used to describe compositions that are strongly influenced by a magnetic field and can retain their magnetic properties (magnetic moment) after the externally applied magnetic field is removed.

[0020] The term "nanoparticle" refers to an object having a diameter of about 2 nm to about 200 nm (e.g., 10 nm to 200 nm, 2 nm to 100 nm, 2 nm to 40 nm, 2 nm to 30 nm, 2 nm to 20 nm, 2 nm to 15 nm, 100 nm to 200 nm, and 150 nm to 200 nm). Non-limiting examples of nanoparticles include the nanoparticles described herein.

[0021] The term "magnetic nanoparticle" means a nanoparticle (e.g., any of the nanoparticles described herein) that is magnetic (as defined herein). Non-limiting examples of magnetic nanoparticles are described herein. Additional magnetic nanoparticles are known in the art.

[0022] The term "nucleic acid" refers to any single- or double-stranded polynucleotide (e.g., DNA or RNA, cDNA, semisynthetic, or synthetic origin). The term nucleic acid includes oligonucleotides containing at least one modified nucleotide (e.g., containing a modification in the base and / or a modification in the sugar) and / or a modification in the phosphodiester bond linking two nucleotides. In some embodiments, a nucleic acid may contain at least one locked nucleotide (LNA). Non-limiting examples of nucleic acids are described herein. Additional examples of nucleic acids are known in the art.

[0023] The term "modified nucleotide" refers to a DNA or RNA nucleotide that contains at least one modification in its base and / or at least one modification in its sugar (ribose or deoxyribose) and can also contain modifications in the atoms that form the phosphodiester bond between two adjacent nucleotides in a nucleic acid sequence.

[0024] The term "polymer coating" refers to at least one (e.g., homogeneous or heterogeneous) molecular layer of at least one polymer (e.g., dextran) applied to the surface of a three-dimensional object (e.g., a three-dimensional object comprising a magnetic material such as a metal oxide). Non-limiting examples of polymers that can be used to produce the polymer coating are described herein. Further examples of polymers that can be used to produce the polymer coating are known in the art. Methods for applying polymer coatings to objects (e.g., three-dimensional objects comprising a magnetic material) are described herein and are also known in the art.

[0025] The phrase "cancer cell invasion" refers to the migration of cancer cells into non-cancerous tissues of a subject. Non-limiting examples of cancer cell invasion include: the migration of cancer cells into lymph nodes, lymphatics, the vasculature (e.g., the adventitia, media, or intima of blood vessels), or epithelial or endothelial tissues. Exemplary methods for detecting and determining cancer cell invasion are described herein. Additional methods for detecting and determining cancer cell invasion are known in the art.

[0026] The term "metastasis" refers to the migration of cancer cells present in a primary tumor to a secondary, non-adjacent tissue in a subject. Non-limiting examples of metastasis include metastasis from a primary tumor to a lymph node (e.g., a regional lymph node), bone tissue, lung tissue, liver tissue, and / or brain tissue. The term metastasis also includes the migration of metastatic cancer cells found in a lymph node to a secondary tissue (e.g., bone tissue, liver tissue, or brain tissue). In some non-limiting embodiments, the cancer cells present in the primary tumor are breast cancer cells, colon cancer cells, kidney cancer cells, lung cancer cells, skin cancer cells, ovarian cancer cells, pancreatic cancer cells, prostate cancer cells, rectal cancer cells, gastric cancer cells, thyroid cancer cells, or uterine cancer cells. Additional aspects and examples of metastasis are known in the art or described herein.

[0027] The term "primary tumor" refers to a tumor present at the anatomical site where tumor development begins and progresses to produce a cancerous mass. In some embodiments, a physician may not be able to clearly identify the site of the primary tumor in a subject.

[0028] The term "metastatic tumor" refers to a tumor in a subject that originates from tumor cells that have metastasized from the subject's primary tumor. In some embodiments, a physician may not be able to clearly identify the site of the primary tumor in a subject.

[0029] The term "lymph node" refers to a small, spherical or oval organ of the immune system that contains a variety of cells, including B lymphocytes, T lymphocytes, and macrophages, and is connected to the lymphatic system by lymphatic vessels. A variety of lymph nodes exist in mammals, including, but not limited to, axillary lymph nodes (e.g., lateral, anterior or pectoral, posterior or subscapular, central or intermediate, or medial or subclavian), sentinel lymph nodes, submandibular lymph nodes, anterior cervical lymph nodes, posterior cervical lymph nodes, supraclavicular lymph nodes, submental lymph nodes, femoral lymph nodes, mesenteric lymph nodes, mediastinal lymph nodes, inguinal lymph nodes, subsegmental lymph nodes, segmental lymph nodes, lobular lymph nodes, interlobar lymph nodes, hilar lymph nodes, supratrochlear gland, deltoideopectoral gland, superficial inguinal lymph nodes, deep inguinal lymph nodes, brachial lymph nodes, and popliteal lymph nodes.

[0030] The term "imaging" refers to the visualization of at least one tissue of a subject using biophysical techniques (e.g., absorption and / or emission of electromagnetic energy). Non-limiting examples of imaging include magnetic resonance imaging (MRI), X-ray computed tomography, and optical imaging.

[0031] The term "subject" or "patient," as used herein, refers to any mammal (e.g., a human or veterinary subject, e.g., a dog, cat, horse, cow, goat, sheep, mouse, rat, or rabbit) to which a composition or method of the present disclosure can be administered, for example, for experimental, diagnostic, prophylactic, and / or therapeutic purposes. A subject may seek or need treatment, request treatment, be undergoing treatment, be undergoing treatment, or be under the care of a trained professional for a particular disease or condition.

[0032] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "nanoparticles" includes mixtures of nanoparticles, reference to "nanoparticles" includes mixtures of two or more such nanoparticles, and so forth.

[0033] Ranges may be expressed herein as from "about" one particular value, and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values ​​are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

[0034] The term "chemotherapeutic agent" refers to a molecule that can be used to reduce the growth rate of, or induce or mediate the death (e.g., necrosis or apoptosis) of, cancer cells in a subject (e.g., a human). In non-limiting examples, a chemotherapeutic agent can be a small molecule, a protein (e.g., an antibody, an antigen-binding fragment of an antibody, or a derivative or conjugate thereof), a nucleic acid, or any combination thereof. Non-limiting examples of chemotherapeutic agents include: cyclophosphamide, mechlorethamine, chlorabcil, melphalan, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, barbican, paclitaxel, docetaxel, etoposide, teniposide, tafluposide, azacitidine, axathioprine, capcitabine, cytarabine, doxifluridine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, thioguanine, bleomycin, carboplatin, cisplatin, oxaliplatin, all-trans retinoic acid, vinblastine, vincristine, vindesine, vinorelbine, bevacizumab (or an antigen-binding fragment thereof). Further examples of chemotherapeutic agents are known in the art.

[0035] The embodiments disclosed below include therapeutic radiolabeled nanoparticles comprising a polymer coating and a covalently attached inhibitory nucleic acid, compositions comprising these therapeutic nanoparticles, methods of using these therapeutic nanoparticles, and methods of preparing these therapeutic nanoparticles. Some embodiments of the therapeutic nanoparticles, compositions, and methods described herein may provide one or more of the following advantages:

[0036] First, certain embodiments of the present disclosure include methods of using any of the nanoparticle compositions for the treatment, prevention, diagnosis, and / or imaging of a disease (e.g., cancer) in a subject in need thereof. Currently, there is a need for improved therapeutic agents that can significantly accumulate in metastatic tissue for therapeutic and / or diagnostic purposes. The therapeutic nanoparticles, compositions, and methods of the present disclosure address this need. For example, in some embodiments, the therapeutic nanoparticles described herein can accumulate in metastatic tissue. In some embodiments, the therapeutic nanoparticles can include a radiolabel that allows imaging of the therapeutic nanoparticles (e.g., via positron emission tomography (PET)). In some embodiments, the therapeutic nanoparticles can further include an inhibitory nucleic acid that can cause complete and sustained regression of metastatic foci. Thus, in some embodiments, the therapeutic nanoparticles of the present disclosure can effectively target metastatic tissue.

[0037] Second, some embodiments described herein may provide sufficient sensitivity (e.g., using PET as an imaging technique) to determine the concentration of radiolabeled drugs with sensitivities approaching the sub-picomolar range. Thus, in some embodiments, therapeutic nanoparticles can be conveniently detected and / or imaged while administering doses as low as one microgram. This property has significant advantages in the early stages of drug development. Because such low doses do not induce adverse side effects, U.S. Food and Drug Administration approval for early human trials can be obtained more quickly and with more limited preclinical safety and toxicology data than is required for therapeutic agents.

[0038] Third, some embodiments described herein may clarify the biodistribution of therapeutic nanoparticles in cancer patients. One of the major challenges facing the development of cancer therapeutics is effective delivery to target organs. In the case of drug delivery to metastases, complicating factors include the large size of the lesions compared to animal models, the heterogeneity of human disease, and differences in drug pharmacokinetics due to hemodynamic variations between species. Based on these differences, it is not possible to directly extrapolate preclinical biodistribution and efficacy data to the successful clinical implementation of a therapeutic agent. Based on the comparable biodistribution of therapeutic microdoses and therapeutic macrodoses (see, e.g., Figures 11A-11D), certain embodiments described herein may clarify the pharmacokinetic behavior of therapeutic nanoparticles without the need to administer doses greater than approximately 0.014 mg / kg, potentially helping to establish dosing during treatment and enabling patient selection for treatment based on which patient's metastases accumulate therapeutic nanoparticles.

[0039] When values ​​are described in this disclosure in terms of ranges, the endpoints are included. Furthermore, whether a specific numerical value or a specific subrange is explicitly set forth, it is to be understood that the description includes disclosure of all possible subranges within such ranges, as well as specific numerical values ​​falling within such ranges.

[0040] Various embodiments of the features of the present disclosure are described herein. However, it should be understood that such embodiments are provided merely by way of example, and that numerous variations, changes, and substitutions may occur according to those skilled in the art without departing from the scope of the present disclosure. It should also be understood that various alternatives to the specific embodiments described herein are within the scope of the present disclosure.

[0041] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Methods and materials are described herein for use in the present invention, but other suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

[0042] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features and advantages of the invention will become apparent from the following detailed description, drawings, and claims. [Brief explanation of the drawings]

[0043] [Figure 1] Figure 1A shows an exemplary therapeutic magnetic nanoparticle with a dextran coating and an antisense LNA oligonucleotide targeting miRNA-10b (MN-anti-miR10b). Figure 1B is a graph showing miR-10b expression levels determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in human metastatic breast cancer cells after 48 hours of incubation with MN-anti-miR10b or the corresponding magnetic nanoparticle containing a scrambled nucleic acid rather than an anti-miR10b nucleic acid (MN-scr-miR). Data shown are expressed as the mean ± standard deviation (n = 3; **, p < 0.01). [Figure 2]Figure 2A is a set of six photomicrographs showing the cellular morphology of human metastatic breast cancer cells 48 hours after treatment with phosphate-buffered saline (PBS) (negative control), low-dose doxorubicin alone (dox), magnetic nanoparticles containing scrambled nucleic acid but not anti-miR10b nucleic acid (MN-scr-miR), magnetic nanoparticles containing scrambled nucleic acid and low-dose doxorubicin (MN-scr-miR+dox), MN-anti-miR10b, and MN-anti-miR10b and low-dose doxorubicin (MN-anti-miR10b+dox). Figure 2B is a graph showing the percentage of apoptotic cells in each of the conditions. Figure 2C is a graph showing the percentage of cell proliferation for each of the conditions. Figure 2D is a set of six graphs of flow cytometry data of human metastatic breast cancer cells showing pre-G1 apoptotic and G2 / M-arrested cell populations for each of the conditions. (Data represent mean ± standard deviation; two-tailed t-test; n = 3). [Figure 3] Figure 3A is a gel electrophoresis image confirming miR-10b knockout, and Figure 3B is a set of six photomicrographs of tumor cells taken 24 and 72 hours after transfection with the knockout vector set (TALEN L+R). [Figure 4] Figure 4A shows a set of seven macroscopic images generated using bioluminescence imaging (BLI) and a set of seven macroscopic images generated using near-infrared fluorescence (NIRF) imaging of a resected organ bearing a metastasis showing accumulation of MN-anti-miR10b. Figure 4B shows a set of seven photomicrographs of the resected organ stained with hematoxylin and eosin (H&E) and a set of seven photomicrographs of the resected organ fluorescently stained with Cy5.5. Figure 4C, on the left, shows BLI and NIRF images of MN-anti-miR10b delivery to brain metastases in vivo; on the right, three fluorescent photomicrographs show accumulation of MN-anti-miR10b (Cy5.5 on MN) in luciferase-expressing tumor cells. [Figure 5-1]Figure 5A is a set of bioluminescence images of metastatic burden in animals treated with PBS (negative control), magnetic nanoparticles containing scrambled nucleic acid rather than anti-miR10b nucleic acid (MN-scr-miR), magnetic nanoparticles containing scrambled nucleic acid and a low dose of doxorubicin (MN-scr-miR+dox), MN-anti-miR10b, and MN-anti-miR10b and a low dose of doxorubicin (MN-anti-miR10b+dox). [Figure 5-2] Figure 5B is a graph showing quantitative analysis of metastatic burden from all treatment groups, demonstrating complete regression of metastatic burden in the lymph nodes of experimental animals after just four weeks of treatment. Background counts were obtained from tumor-free animals. Figure 5C is a set of bioluminescent images and photographs of ex vivo organs showing the absence of detectable lymph node or lung metastases in mice treated with MN-anti-miR10b+dox. Control treatments included PBS, MN-scr-miR, MN-scr-miR+dox, and MN-anti-miR10b. Figure 5D is a graph showing mouse weights throughout the time course of the study. Figure 5E is a graph showing the survival probability of mice treated with PBS, MN-scr-miR, MN-scr-miR+dox, MN-anti-miR10b, and MN-anti-miR10b+dox. (Data represent mean ± standard error; within-subject ANOVA: p<0.05. PBS, n=2; MN-scr-miR, n=6; MN-scrmiR+dox, n=10; MN-anti-miR10b, n=7; MN-anti-miR10b+dox, n=10). [Figure 6] Figure 6A is a set of bioluminescent images of mice showing metastatic burden. Figure 6B is a graph showing quantitative analysis of relative metastatic burden across all treatment groups. Figure 6C is a graph showing survival rates for mice treated with PBS, HD Dox, MN-scr-miR+dox, and MN-anti-miR10b+dox. Figure 6D is a set of three images of post-necropsy lungs showing no evidence of lung metastases in animals treated with MN-anti-miR10b. [Figure 7]Figure 7 is a schematic diagram showing the preparation of nat / 64Cu-MN-anti-miR10b: Step 1. Coupling reaction of MN-NH2 with NODAGA-NHS to form NODAGA-MN. Step 2. Functionalization with the heterobifunctional linker SPDP. Step 3. Conjugation with anti-miR10b antagomir via a disulfide bond to form NODAGA-MN-anti-miR10b. Step 4. Complexation with natCuCl2 or 64CuCl2 to yield nat / 64Cu-MN-anti-miR10b. [Figure 8] Figure 8A shows graphs demonstrating radiochemical purity confirmed by iTLC; (top) unlabeled Cu-64, (middle) separation of 64Cu-MN-anti-miR10b and unlabeled Cu-64, and (bottom) 64Cu-MN-anti-miR10b after PD-10 purification. Figure 8B shows the high-performance liquid chromatography (HPLC) trace (top) and UV trace at 254 nm (bottom) of 64Cu-MN-anti-miR10b using size-exclusion chromatography. Figure 8C is a set of two transmission electron microscopy (TEM) images of Cu-MN-anti-miR10b and natCu-MN-anti-miR10b. Figure 8D is a graph showing nanoparticle size characterized by TEM and dynamic light scattering (DLS). Figure 8E is a graph showing in vitro cellular uptake by breast adenocarcinoma cells. Figure 8F is a graph showing the level of relative miR-10b expression determined by qRT-PCR, indicating target association (inhibition of miR-10b). natCu was used for the preparation of natCu-MN-anti-miR10b (t-test, n=3, **P<0.01). [Figure 9] FIG. 9 is a schematic exemplary synthetic route for radiolabeling of MN-anti-miR10b nanoparticles. [Figure 10] FIG. 10 is an exemplary set of chelators that can be used to prepare magnetic radiolabeled nanoparticles of the present disclosure. [Figure 11]Figure 11A shows the ex vivo biodistribution (%ID / g) of 64Cu-MN-anti-miR10b measured 24 and 48 hours after microdose administration. Figure 11B shows the ex vivo biodistribution (%ID / g) of 64Cu-MN-anti-miR10b measured 24 and 48 hours after macrodose administration of 64Cu-MN-anti-miR10b in therapeutic vehicle. The inset shows the %ID / g values ​​in the liver and spleen. # indicates organs with metastases detected by BLI. Error bars represent the standard error of the mean. Figures 11C and 11D show the correlation between the %ID / g of non-metastatic organs obtained after microdose administration and the %ID / g obtained after macrodose administration at 24 hours (Figure 11C) and 48 hours (Figure 11D) after injection (Pearson product-moment correlations; dashed lines correspond to the same line). [Figure 12] Figures 12A, 12B, and 12C are graphs showing time-activity curves obtained from positron emission tomography (PET) images of the heart (Figure 12A), kidney (Figure 12B), and liver (Figure 12C) of mice (n=3) administered a microdose of 64Cu-MN-anti-miR10b from 5 minutes to 48 hours post-injection. Error bars represent standard deviation. [Figure 13] Figure 13A shows the biodistribution of 64Cu-MN-anti-miR10b injected at microdose and standard therapeutic dose (macrodose) measured 24 hours after injection. Figure 13B shows the biodistribution of 64Cu-MN-anti-miR10b injected at microdose and standard therapeutic dose (macrodose) measured 48 hours after injection. # indicates organ with metastasis detected by BLI. Results are expressed as %ID / g. Error bars represent standard deviation. (t-test, *P<0.05, **P<0.01). [Figure 14]Figure 14A shows a set of in vivo PET-MRI maximum intensity projection (MIP) images of a mouse bearing metastatic breast adenocarcinoma 24 hours after microdose or macrodose injection of 64Cu-MN-anti-miR10b. Yellow arrows point to bone or lymph node (LN) metastases. Figure 14B shows a graph quantification of 64Cu-MN-anti-miR10b accumulation in metastatic (Mets+) and nonmetastatic (Mets-) organs (%ID / cc) obtained from in vivo PET images 24 hours after injection. Higher signal intensity in metastatic organs compared with nonmetastatic organs confirms uptake of the therapeutic agent by metastatic lesions. Open circles represent mice injected with a microdose, and filled circles represent mice injected with a macrodose. Figure 14C shows a set of ex vivo PET-MRI images of bone and lymph node metastases. From left: in vivo BLI, ex vivo PET, and ex vivo white-light photographs of metastatic lesions. FIG. 14D is a set of ex vivo images of the biodistribution of 64Cu-MN-anti-miR10b visualized by PET 48 hours after microdose injection and 24 hours after macrodose injection. [Figure 15] FIG. 15 is a graph showing time-activity curves obtained from PET imaging 5 minutes to 48 hours after injection of a microdose of 64Cu-MN-anti-miR10b in metastatic (Mets+) and non-metastatic (Mets-) bone (n=3). DETAILED DESCRIPTION OF THE INVENTION

[0044] The therapeutic nanoparticles described herein have been found to detect cancer metastasis in mammals and reduce cancer cell invasion and cancer metastasis in mammals. Therapeutic nanoparticles with these activities are provided herein, as well as methods for reducing cancer cell invasion or metastasis in a subject, methods for treating metastatic cancer to lymph nodes in a subject, and methods for detecting, diagnosing, and / or monitoring metastatic cancer tissue in a subject by administering these therapeutic nanoparticles. Methods for preparing the therapeutic nanoparticles of the present disclosure are also provided herein.

[0045] composition Provided herein are therapeutic nanoparticles comprising a chelator covalently attached to the therapeutic nanoparticle and a radiolabel, and a nucleic acid molecule covalently attached to the therapeutic nanoparticle.

[0046] Chelator The therapeutic nanoparticles described herein can include at least one chelator covalently attached to the therapeutic nanoparticle. In some embodiments, the chelator forms a stable complex with the radiolabel. In some embodiments, the chelator is bound to the radiolabel.

[0047] In some embodiments, therapeutic nanoparticles may include from about 1 chelator to about 15 chelators covalently attached to each therapeutic nanoparticle (e.g., from about 1 chelator to about 11 chelators, from about 1 chelator to about 12 chelators, from about 1 chelator to about 13 chelators, from about 1 chelator to about 14 chelators, from about 1 chelator to about 15 chelators, from about 11 chelators to about 12 chelators, from about 11 chelators to about 13 chelators, from about 11 chelators to about 14 chelators, or from about 11 chelators to about 15 chelators). In some embodiments, therapeutic nanoparticles may include about 13 chelators covalently attached to each therapeutic nanoparticle.

[0048] A variety of different chelators that can be covalently attached to therapeutic nanoparticles are known in the art, including, but not limited to, 1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid (NODAGA), 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA), 10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid. Acid (DOTA-GA), 2-[4,7,10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid (p-SCN-Bn)-DOTA, 2,2'-(1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diyl)diacetic acid (CB-TE2A), CB-TE1A1P, 1 , 4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-methylperhydro-1,4-diazepine (AAZTA), 5-(8-methyl-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar), 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn)-NOTA, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid) (HBED-CC), tris(hydroxypyridinone) (THP), MAS3, and desferoxamine (DFO).

[0049] Additional chelators are also described in Price and Ovig (Chem. Soc. Rev., 2014, 43, 260-290), Boros and Packard (Chem. Rev. 2019, 119, 2, 870-901), Barndt et al. (J. Nucl. Med., 2018, 59, 1500-1506), and Sneddon and Cornelissen (Curr. Opin. Chem. Biol., 2021, 63, 152-162), each of which is incorporated by reference in its entirety.

[0050] In some embodiments, the chelator is attached to the therapeutic nanoparticle via a chemical moiety that includes a primary amine, a secondary amine, an amide, a thioester, or a disulfide bond. Additional chemical moieties that can be used to covalently attach a chelator to a therapeutic nanoparticle are known in the art.

[0051] A variety of different methods can be used to covalently bind chelators to therapeutic nanoparticles. In some embodiments, fluorophores are attached to therapeutic nanoparticles through the reaction of an amine group (present in the chelator or on the therapeutic nanoparticle) with an active ester, carboxylate, isothiocyanate, or hydrazine (e.g., present in the chelator or on the therapeutic nanoparticle); a carboxyl group (e.g., present in the chelator or on the therapeutic nanoparticle) in the presence of a carbodiimide; a thiol (e.g., present in the chelator or on the therapeutic nanoparticle) in the presence of a maleimide; a thiol (e.g., present in the chelator or on the therapeutic nanoparticle) in the presence of a maleimide or acetyl bromide; or an azide (e.g., present in the chelator or on the therapeutic nanoparticle) in the presence of glutaraldehyde. Additional methods for binding chelators to therapeutic nanoparticles are known in the art.

[0052] In some embodiments, the therapeutic nanoparticles do not include a chelator. In some embodiments, the therapeutic nanoparticles may include a radiolabel that is directly associated (e.g., covalently attached) to the therapeutic nanoparticles.

[0053] radioactive label The therapeutic nanoparticles described herein comprise a radiolabel. In some embodiments, the radiolabel can be associated with the nanoparticle. For example, in some embodiments, the radiolabel can be covalently or non-covalently attached to the therapeutic nanoparticle via a linker. In some embodiments, the radiolabel can be directly covalently or non-covalently attached to the therapeutic nanoparticle. In some embodiments, the radiolabel can be associated with the therapeutic nanoparticle or a composition or moiety surrounding the therapeutic nanoparticle (e.g., via van der Waals forces). In some embodiments, the radiolabel can be associated with the therapeutic nanoparticle without the use of a chelator (e.g., when the therapeutic nanoparticle is chelator-free). In some embodiments, the radiolabel can be associated with the therapeutic nanoparticle using a chelator. In some embodiments, the radiolabel forms a stable complex with the chelator.

[0054] In some embodiments, therapeutic nanoparticles may comprise from about 1 radiolabeled atom to about 15 radiolabeled atoms (e.g., from about 1 radiolabeled atom to about 11 radiolabeled atoms, from about 1 radiolabeled atom to about 12 radiolabeled atoms, from about 1 radiolabeled atom to about 13 radiolabeled atoms, from about 1 radiolabeled atom to about 14 radiolabeled atoms, from about 1 radiolabeled atom to about 15 radiolabeled atoms, from about 13 radiolabeled atoms to about 14 radiolabeled atoms, from about 13 radiolabeled atoms to about 15 radiolabeled atoms) per therapeutic nanoparticle. In some embodiments, therapeutic nanoparticles may comprise about 14 radiolabeled atoms associated with each nanoparticle (e.g., via a chelator).

[0055] In some embodiments, the radiolabel has an emission energy (e.g., β) in the range of about 550 kiloelectron volts (keV) to about 3500 keV (e.g., about 550 keV to about 580 keV, about 550 keV to about 640 keV, about 550 keV to about 660 keV, about 550 keV to about 770 keV, about 550 keV to about 910 keV, about 579 keV to about 1200 keV, about 579 keV to about 1900 keV, about 579 keV to about 3500 keV). + In some embodiments, the radiolabel has an emission energy of about 656 keV. In some embodiments, the radiolabel has an emission energy similar to that of fluorine-18 (F-18) (e.g., ±25 keV). In some embodiments, the radiolabel has an emission energy of about 656 keV.

[0056] In some embodiments, the radiolabel has a half-life that allows for adequate assessment of slow pharmacokinetics of macromolecules and / or blood pool agents. In some embodiments, the radiolabel has a half-life ranging from about 10 minutes to about 80 hours (e.g., about 10 minutes to about 13 hours, about 70 minutes to about 13 hours, about 110 minutes to about 13 hours, about 13 hours to about 26 hours, about 13 hours to about 80 hours). In some embodiments, the radiolabel has a half-life of about 12.7 hours.

[0057] A variety of different radiolabels that can be associated (e.g., covalently or non-covalently bound) with therapeutic nanoparticles are known in the art. Non-limiting examples of such chelators include copper-64 (Cu-64), F-18, scandium-44 (Sc-44), cobalt-55 (Co-55), niobium-90 (Nb-90), rhenium-188 (Re-188), thallium-201 (Tl-201), copper-67 (Cu-67), yttrium-90 (Y-90), terbium-161 (Tb-161), lutetium-177 (Lu-177), bismuth-213 (Bi-213), lead-212 (Pb-212), actinium-225 (Ac-225), and zirconium-89 (Zr). In some embodiments, the radiolabel is Cu-64.

[0058] nucleic acid Therapeutic nanoparticles provided herein comprise at least one nucleic acid molecule covalently attached to the nanoparticle, the nucleic acid molecule comprising at least 10 (e.g., at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22) consecutive nucleotides within the sequence of precursor microRNA-10b (miR-10b). In some embodiments, the nucleic acid molecule comprises the sequence of precursor miR-10b. In some embodiments, the therapeutic nanoparticle may comprise a sequence that is complementary to at least 10 (e.g., at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) consecutive nucleotides within the sequence of precursor miR-10b.

[0059] In some embodiments, the nucleic acid molecule in the therapeutic nanoparticle comprises the sequence(s) of miR-21, miR-15, miR-16, miR-17, miR-18, miR-19a, miR-19b, miR-20, miR-92, miR-106, miR-191, miR-125b, miR-155, miR-569, miR-196b, or any combination thereof. In some embodiments, the nucleic acid contained in the therapeutic nanoparticle may comprise a sequence of at least 10 (e.g., at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) contiguous nucleotides in a sequence complementary to mature human miR-21, miR-15, miR-16, miR-17, miR-18, miR-19a, miR-19b, miR-20, miR-92, miR-106, miR-191, miR-125b, miR-155, miR-569, miR-196b, or any combination thereof. In some embodiments, the therapeutic nanoparticles may comprise a sequence complementary to at least 10 (e.g., at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) consecutive nucleotides within the sequence of mature human miR-21, miR-15, miR-16, miR-17, miR-18, miR-19a, miR-19b, miR-20, miR-92, miR-106, miR-191, miR-125b, miR-155, miR-569, miR-196b, or any combination thereof.

[0060] The bound nucleic acid can be single-stranded or double-stranded. In some embodiments, the nucleic acid comprises a portion of the sequence of precursor miR-10b and has a total length of 23 to 50 nucleotides (e.g., 23 to 30 nucleotides, 30 to 40 nucleotides, and 40 to 50 nucleotides). In some embodiments, the nucleic acid comprises a sequence complementary to at least a portion of the sequence of precursor miR-10b and has a total length of 22 to 50 nucleotides (e.g., 22 to 30 nucleotides, 30 to 40 nucleotides, and 40 to 50 nucleotides). In some embodiments, the nucleic acid can be an antisense RNA (e.g., an antagomir).

[0061] Antisense nucleic acid molecules can be covalently bound to the therapeutic nanoparticles described herein. For example, in some embodiments, the nucleic acid molecule can comprise at least a portion (e.g., at least 10 nucleotides) of a sequence complementary to the sequence of mature human miR-10b, and in some embodiments, the nucleic acid molecule can comprise at least a portion (e.g., at least 10 nucleotides) of a sequence complementary to the sequence of a minor form of mature human miR-10b. In some embodiments, the therapeutic nanoparticles can comprise nucleic acid molecules that target human miR-10b for downregulation.

[0062] In some embodiments, the therapeutic nanoparticles can comprise any of a number of suitable antisense molecules (e.g., antisense molecules targeting mature human miR-10b). For example, an antisense nucleic acid targeting miR-10b can comprise a sequence complementary to at least 10 (e.g., at least 15 or 20) consecutive nucleotides present in a sequence for miR-10b known in the art.

[0063] Antisense nucleic acids can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, antisense nucleic acids (e.g., antisense oligonucleotides) can be chemically synthesized using naturally occurring nucleotides or modified nucleotides (e.g., any of the modified oligonucleotides described herein) designed to increase the biological stability of the molecule or to increase the physical stability of the duplex formed between antisense nucleic acids and sense nucleic acids, for example, phosphorothioate derivatives and acridine-substituted nucleotides can be used. Alternatively, antisense nucleic acids can be biologically produced using an expression vector into which a nucleic acid is subcloned in antisense orientation (i.e., the RNA transcribed from the inserted nucleic acid is in antisense orientation to the target nucleic acid of interest). In some embodiments, the antisense nucleic acid molecules described herein can hybridize to target nucleic acids through conventional nucleotide complementarity to form a stable duplex.

[0064] Antisense nucleic acid molecules can be α-anomeric nucleic acid molecules.α-anomeric nucleic acid molecules form specific double-stranded hybrids with complementary RNA, where, unlike the usual β-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids Res. 15:6625-6641, 1987).Antisense nucleic acid molecules can also contain 2'-O-methylribonucleotides (Inoue et al., Nucleic Acids Res., 15:6131-6148, 1987) or chimeric RNA-DNA analogs (Inoue et al., FEBS Lett. 215:327-330, 1987).

[0065] In some embodiments, a nucleic acid molecule may contain at least one modified nucleotide (a nucleotide containing a modified base or sugar). In some embodiments, a nucleic acid molecule may contain at least one modification in the phosphate (phosphodiester) backbone. Introduction of these modifications may increase the stability of the nucleic acid molecule or improve hybridization or solubility.

[0066] The molecules described herein can contain one or more (e.g., two, three, four, five) modified nucleotides. Modified nucleotides can contain modified bases or modified sugars. Non-limiting examples of modified bases include: 8-oxo-N 6 -methyladenine, 7-deazaxanthine, 7-deazaguanine, N 4 ,N 4 -Ethanocytosine, N 6 ,N 6 -Ethano-2,6-diaminopurine, 5-(C 3 -C 6)-Alkynyl-cytosine, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridine, isocytosine, isoguanine, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6 -adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosin, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthioN6-isopentenyladenine, uracil-5-oxyacetic acid(v), wibutoxosin, pseudouracil, quosin, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid(v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, (acp3)w, and 2,6-diaminopurine.

[0067] Further non-limiting examples of modified bases include the nucleobases described in U.S. Pat. Nos. 5,432,272 and 3,687,808 (incorporated herein by reference), Freier et al., Nucleic Acid Res. 25:4429-4443, 1997; Sanghvi, Antisense Research and Application, Chapter 15, Ed. ST Crooke and B. Lebleu, CRC Press, 1993; Englisch, et al., Angewandte Chemie 30:613-722, 1991, Kroschwitz, Concise Encyclopedia of Polymer Science and Engineering, John Wiley & Sons, pp. 858-859, 1990; and Cook, Anti-Cancer Drug Design 6:585-607, 1991. Further non-limiting examples of modified bases include universal bases (e.g., 3-nitropyrrole and 5-nitroindole). Other modified bases include pyrene and pyridyloxazole derivatives, pyrenyl, pyrenylmethylglycerol derivatives, and the like. Other preferred universal bases include pyrrole, diazole, or triazole derivatives, including universal bases known in the art.

[0068] In some embodiments, a modified nucleotide may contain a modification in its sugar moiety. A non-limiting example of a modified nucleotide containing a modified sugar is a locked nucleotide (LNA). LNA monomers are described in WO 99 / 14226 and U.S. Patent Application Publication Nos. 20110076675, 20100286044, 20100279895, 20100267018, 20100261175, 20100035968, 20090286753, 20090023594, 20080096191, 20030092905, 20020128381 and 20020115080, which are incorporated herein by reference.Further non-limiting examples of LNAs are described in U.S. Pat. No. 6,043,060, U.S. Pat. No. 6,268,490, WO 01 / 07455, WO 01 / 00641, WO 98 / 39352, WO 00 / 56746, WO 00 / 56748, and WO 00 / 66604 (incorporated herein by reference), as well as Morita et al., Bioorg. Med. Chem. Lett. 12(1):73-76, 2002; Hakansson et al., Bioorg. Med. Chem. Lett. 11(7):935-938, 2001; Koshkin et al., J. Org. Chem. 66(25):8504-8512, 2001; Modified nucleotides are disclosed in Kvaerno et al., J. Org. Chem. 66(16):5498-5503, 2001; Häkansson et al., J. Org. Chem. 65(17):5161-5166, 2000; Kvaerno et al., J. Org. Chem. 65(17):5167-5176, 2000; Pfundheller et al., Nucleosides Nucleotides 18(9):2017-2030, 1999; and Kumar et al., Bioorg. Med. Chem. Lett. 8(16):2219-2222, 1998. In some embodiments, the modified nucleotide is an oxyLNA monomer, such as those described in WO 03 / 020739.

[0069] Modified nucleotides also include antagomir (2'-O-methyl modified, cholesterol-conjugated single-stranded RNA analogs); ALN (α-L-LNA); ADA (2'-N-adamantylmethylcarbonyl-2'-amino LNA); PYR (2'-N-pyrenyl-1-methyl-2'-amino-LNA); OX (oxetane-LNA); ENA (2'-O,4''-C-ethylene bridged nucleic acid); AENA (2'-deoxy-2'-N,4'-C-ethylene-LNA); CLNA (2',4'-carbocyclic LNA); and C These may include ENA (2',4'-carbocyclic ENA); HM-modified DNA (4'-C-hydroxymethyl-DNA); 2'-substituted RNA (2'-O-methyl, 2'-fluoro, 2'-aminoethoxymethyl, 2'-aminopropoxymethyl, 2'-aminoethyl, 2'-guanidinoethyl, 2'-cyanoethyl, 2'-aminopropyl); and RNA with radical modifications of the ribose sugar ring, such as unlocked nucleic acid (UNA), altritol nucleic acid (ANA), and hexitol nucleic acid (HNA) (see Bramsen et al., Nucleic Acids Res. 37:2867-81, 2009).

[0070] The molecules described herein can also include modifications to the phosphodiester backbone, for example, at least one linkage between any two consecutive (adjacent) nucleotides in the molecule can be: -CH2-, -O-, -S-, -NR H -, >C=O, >C=NR H , >C=S, -Si(R'')2-, -SO-, -S(O)2-, -PO(BH3)-, -P(O,S)-, -P(S)2-, -PO(R'')-, -PO(OCH3)-, and -PO(NHR H )-, wherein R H is hydrogen and C 1-4 -alkyl, and R'' is selected from C 1-6-alkyl and phenyl. Illustrative examples of such linkages are -CH-CH-CH-, -CH-CO-CH-, -CH-CHOH-CH-, -O-CH-O-, -O-CH-CH-, -O-CH-CH=(R 5 including -CH2-CH2-O-, -NR H -CH2-CH2-, -CH2-CH2-NR H -, -CH2-NR H -CH2-, -O-CH2-CH2-NR H -, -NR H -CO-O-, -NR H -CO-NR H -, -NR H -CS-NR H -, -NR H -C(=NR H )-NR H -, -NR H -CO-CH2-NR H -, -O-CO-O-, -O-CO-CH2-O-, -O-CH2-CO-O-, -CH2-CO-NR H -, -O-CO-NR H -, -NR H -CO-CH2-, -O-CH2-CO-NR H -, -O-CH2-CH2-NR H -, -CH=NO-, -CH2-NR H -O-, -CH2-ON = (R when used as a link to a subsequent monomer) 5 including -CH2-O-NR H -, -CO-NR H -CH2-, -CH2-NR H -O-, -CH2-NR H -CO-, -O-NR H -CH2-, -O-NR H -, -O-CH2-S-, -S-CH2-O-, -CH2-CH2-S-, -O-CH2-CH2-S-, -S-CH2-CH=(R when used as a link to a subsequent monomer) 5), -S-CH2-CH2-, -S-CH2-CH2-O-, -S-CH2-CH2-S-, -CH2-S-CH2-, -CH2-SO-CH2-, -CH2-SO2-CH2-, -O-SO-O-, -OS(O)2-O-, -OS(O)2-CH2-, -OS(O)2-NR H -, -NR H -S(O)2-CH2-, -OS(O)2-CH2-, -OP(O)2-O-, -OP(O,S)-O-, -OP(S)2-O-, -SP(O)2-O-, -SP(O,S)-O-, -SP(S)2-O-, -OP(O,S)-S-, -OP(S)2-S-, -SP (O)2-S-, -SP(O,S)-S-, -SP(S)2-S-, -O-PO(R'')-O-, -O-PO(OCH3)-O-, -O-PO-(OCH2CH3)-O-, -O-PO(OCH2S-R)-O-, -O-PO(BH3)-O-, -O-PO(NHR N )-O-, -OP(O)2-NR H -, -NR H -P(O)2-O-, -OP(O,NR H )2-O-, -CH2-P(O)2-O-, -OP(O)2-CH2-, and -O-Si(R'')2-O-; in particular, -CH2-CO-NR H -, -CH2-NR H -O-, -S-CH2-O-, -OP(O)2-O-, -OP(O,S)-O-, -OP(S)2-O-, -NR H -P(O)2-O-, -OP(O,NR H )-O-, -O-PO(R'')-O-, -O-PO(CH3)-O-, and -O-PO(NHR N )-O-, where R H is hydrogen and C 1-4 -alkyl, and R'' is selected from C 1-6-alkyl and phenyl. Further illustrative examples are shown in Mesmaeker et al., Curr. Opin. Struct. Biol. 5:343-355, 1995; and Freier et al., Nucleic Acids Research 25:4429-43, 1997. The left side of the internucleoside bond contains a substituent P at the 3'-position. * to the five-membered ring, while the right side is attached to the 5'-position of the preceding monomer.

[0071] In some embodiments, the deoxyribose phosphate backbone of nucleic acids can be modified to produce peptide nucleic acids (see Hyrup et al., Bioorganic & Medicinal Chem. 4(1): 5-23, 1996). Peptide nucleic acids (PNAs) are nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced with a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs allows for specific hybridization to DNA and RNA under conditions of low ionic strength. PNA oligomers can be synthesized using standard solid-phase peptide synthesis protocols, e.g., as described in Hyrup et al., 1996, supra; Perry-Keefe et al., Proc. Natl. Acad. Sci. USA 93:14670-675, 1996.

[0072] PNAs can be modified to enhance their stability or cellular uptake, for example, by attaching lipophilic or other helper groups to PNAs, by forming PNA-DNA chimeras, or by using liposomes or other delivery techniques known in the art. For example, PNA-DNA chimeras can be produced to combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, such as RNAse H, to interact with the DNA portion while the PNA portion provides high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate length selected in terms of base stacking, the number of internucleobase bonds, and orientation (Hyrup, 1996, supra). PNA-DNA chimeras can be synthesized as described in Hyrup, 1996, supra, and Finn et al., Nucleic Acids Res. 24:3357-63, 1996. For example, DNA strands can be synthesized on solid supports using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite can be used as a linker between PNA and the 5' end of DNA (Mag et al., Nucleic Acids Res., 17:5973-88, 1989). PNA monomers are then coupled stepwise to produce chimeric molecules with 5' PNA segments and 3' DNA segments (Finn et al., Nucleic Acids Res. 24:3357-63, 1996). Alternatively, chimeric molecules can be synthesized with 5' DNA segments and 3' PNA segments (Peterser et al., Bioorganic Med. Chem. Lett. 5:1119-11124, 1975).

[0073] In some embodiments, any of the nucleic acids described herein can be modified at either the 3' or 5' end (depending on how the nucleic acid is covalently attached to the therapeutic nanoparticle) with any type of modification known in the art. For example, either end can be capped with a protecting group, attached to a flexible linking group, or attached to a reactive group to aid in attachment to a substrate surface (polymer coating).Non-limiting examples of 3' or 5' blocking groups include: 2-amino-2-oxyethyl, 2-aminobenzoyl, 4-aminobenzoyl, acetyl, acetyloxy, (acetylamino)methyl, 3-(9-acridinyl), tricyclo[3.3.1(3,7)]dec-1-yloxy, 2-aminoethyl, propenyl, (9-anthracenylmethoxy)carbonyl, (1,1-dimethylpropoxy)carbonyl, (1,1-dimethylpropoxy). Carbonyl, [1-methyl-1-[4-(phenylazo)phenyl]ethoxy]carbonyl, bromoacetyl, (benzoylamino)methyl, (2-bromoethoxy)carbonyl, (diphenylmethoxy)carbonyl, 1-methyl-3-oxo-3-phenyl-1-propenyl, (3-bromo-2-nitrophenyl)thio, (1,1-dimethylethoxy)carbonyl, [[(1,1-dimethylethoxy)carbonyl]amino]ethyl, 2-(phenylmethoxy)phenyl noxy, (1=[1,1'-biphenyl]-4-yl-1-methylethoxy)carbonyl, bromo, (4-bromophenyl)sulfonyl, 1H-benzotriazol-1-yl, [(phenylmethyl)thio]carbonyl, [(phenylmethyl)thio]methyl, 2-methylpropyl, 1,1-dimethylethyl, benzoyl, diphenylmethyl, phenylmethyl, carboxyacetyl, aminocarbonyl, chlorodifluoroacetyl, trifluoromethyl, cyclohexylcarbonyl, cycloheptyl, cyclohexyl, cyclohexylacetyl, chloro, carboxymethyl, cyclopentylcarbonyl, cyclopentyl, cyclopropylmethyl, ethoxycarbonyl, ethyl, fluoro, formyl, 1-oxohexyl, iodo, methyl, 2-methoxy-2-oxoethyl, nitro, azido, phenyl, 2-carboxybenzoyl, 4-pyridinylmethyl, 2-piperidinyl, propyl, 1-methylethyl, sulfo, and ethenyl. Further examples of 5' and 3' blocking groups are known in the art. In some embodiments, the 5' or 3' blocking group protects the molecule from nuclease degradation.

[0074] In some embodiments, the nucleic acid molecule in the therapeutic nanoparticle can be a small interfering RNA (siRNA). RNAi is a process by which RNA is degraded in host cells. To reduce RNA expression, double-stranded RNA (dsRNA) containing a sequence corresponding to a portion of a target RNA (e.g., mature human miR-10b) is introduced into cells. The dsRNA is digested into 21-23 nucleotide-long duplexes called short interfering RNAs (or siRNAs), which bind to a nuclease complex to form what is known as the RNA-induced silencing complex (or RISC). RISC targets the endogenous target RNA through base-pairing interactions between one strand of the siRNA and the endogenous RNA. The RISC then cleaves the endogenous RNA approximately 12 nucleotides from the 3' end of the siRNA (see Sharp et al., Genes Dev. 15:485-490, 2001, and Hammond et al., Nature Rev. Gen. 2:110-119, 2001).

[0075] siRNAs can be generated using standard molecular biology techniques. Short interfering RNAs can be chemically synthesized, recombinantly produced by expressing RNA from a template DNA, such as a plasmid, or obtained from commercial vendors, such as Dharmacon. RNAs used to mediate RNAi can contain modified nucleotides, such as phosphorothioate nucleotides (e.g., any of the modified nucleotides described herein). The siRNA molecules used to reduce the level of mature human miR-10b can vary in many ways. For example, they can contain a 3' hydroxyl group and a stretch of 21, 22, or 23 contiguous nucleotides. They can be blunt-ended or contain overhanging ends at either the 3', 5', or both ends. For example, at least one strand of the RNA molecule can have a 3' overhang of about 1 to about 6 nucleotides in length (e.g., 1-5, 1-3, 2-4, or 3-5 nucleotides (either pyrimidine or purine nucleotides)). If both strands contain overhangs, the length of the overhangs can be the same or different for each strand.

[0076] To further enhance the stability of the RNA duplex, the 3' overhangs can be stabilized against degradation (e.g., by including purine nucleotides such as adenosine or guanosine nucleotides, or by replacing pyrimidine nucleotides with modified nucleotides (e.g., substitution of uridine dinucleotide 3' overhangs with 2'-deoxythymidine is tolerated and does not affect the efficiency of RNAi)). Any siRNA can be used as long as it has sufficient homology to the target of interest. There is no upper limit to the length of the siRNA that can be used (e.g., siRNAs can range from about 21-50, 50-100, 100-250, 250-500, or 500-1000 base pairs).

[0077] In some embodiments, the nucleic acid molecule in the therapeutic nanoparticle can be an miRNA mimic. Non-limiting examples of miRNA mimics include miRNA mimics of let7, miR-34a, miR-200c, miR-221 / 222, miR-126, miR-29, or any combination thereof. In some embodiments, the nucleic acid molecule in the therapeutic nanoparticle can be an immunostimulatory nucleic acid. In some embodiments, the immunostimulatory nucleic acid is an immunostimulatory RNA, an immunostimulatory DNA, or a combination thereof.

[0078] The nucleic acids described herein can be synthesized using any method known in the art for synthesizing nucleic acids (see, e.g., Usman et al., J. Am. Chem. Soc. 109:7845, 1987; Scaringe et al., Nucleic Acid Res. 18:5433, 1990; Wincott et al., Methods Mol. Biol. 74:59, 1997; and Milligan, Nucleic Acid Res. 21:8783, 1987). These typically utilize common nucleic acid protecting and coupling groups. Synthesis can be performed on commercially available equipment designed for this purpose, such as the 394 Applied Biosystems, Inc. synthesis machine, using protocols provided by the manufacturer. Additional methods for synthesizing the molecules described herein are known in the art. Alternatively, nucleic acids can be custom-ordered from commercial vendors that synthesize oligonucleotides.

[0079] In some embodiments, the nucleic acid is attached to the therapeutic nanoparticle at its 5' end. In some embodiments, the nucleic acid is attached to the therapeutic nanoparticle at its 3' end. In some embodiments, the nucleic acid is attached to the therapeutic nanoparticle via a base present in the nucleic acid.

[0080] In some embodiments, a nucleic acid (e.g., any of the nucleic acids described herein) is attached to a therapeutic nanoparticle (e.g., the polymer coating of a therapeutic nanoparticle) through a chemical moiety that includes a thioether bond or a disulfide bond. In some embodiments, a nucleic acid is attached to a therapeutic nanoparticle through a chemical moiety that includes an amide bond. Additional chemical moieties that can be used to covalently attach a nucleic acid to a therapeutic nanoparticle are known in the art.

[0081] Nucleic acids can be covalently linked to therapeutic nanoparticles using a variety of different methods.Non-limiting examples of methods that can be used to link nucleic acids to magnetic particles include those described in European Patent No. 0937097; U.S. Patent Application Reissue No. 41005; Lund et al., Nucleic Acid Res. 16:10861, 1998; Todt et al., Methods Mol. Biol. 529:81-100, 2009; Brody et al., J. Biotechnol. 74:5-13, 2000; Ghosh et al., Nucleic Acids Res. 15:5353-5372, 1987; U.S. Patent Nos. 5,900,481; 7,569,341; 6,995,248; 6,818,394; 6,811,980; 5,900,481; and 4,818,681 (each of which is incorporated by reference in its entirety). In some embodiments, carbodiimides are used for terminal attachment of nucleic acids to therapeutic nanoparticles. In some embodiments, nucleic acids are attached to therapeutic nanoparticles through the reaction of one of their bases with an activated moiety present on the surface of the therapeutic nanoparticles (e.g., the reaction of an electrophilic base with a nucleophilic moiety on the surface of the therapeutic nanoparticles, or the reaction of a nucleophilic base with an electrophilic residue on the surface of the therapeutic nanoparticles). In some embodiments, 5'-NH2-modified nucleic acids are attached to therapeutic nanoparticles containing CNBr-activated hydroxyl groups (see, e.g., Lund et al., supra). Further methods for attaching amino-modified nucleic acids to therapeutic nanoparticles are described below. In some embodiments, 5'-phosphate nucleic acids are attached to therapeutic nanoparticles containing hydroxyl groups in the presence of carbodiimides (see, e.g., Lund et al., supra). Other methods for attaching nucleic acids to therapeutic nanoparticles include carbodiimide-mediated attachment of 5'-phosphate nucleic acids to NH groups on therapeutic nanoparticles and carbodiimide-mediated attachment of 5'-NH nucleic acids to therapeutic nanoparticles with carboxyl groups (see, e.g., Lund et al., supra).

[0082] In exemplary method, can produce nucleic acid that contains reactive amine or reactive thiol group.Amine or thiol in nucleic acid can be linked with another reactive group.Two common strategies for carrying out this reaction are to link nucleic acid with similar reactive moiety (amine to amine or thiol to thiol), which is called homobifunctional linkage, or to link nucleic acid with opposite group (amine to thiol or thiol to amine), which is called heterobifunctional linkage. Either technique can be used to attach nucleic acids to therapeutic nanoparticles (e.g., Misra et al., Bioorg. Med. Chem. Lett. 18:5217-5221, 2008; Mirsa et al., Anal. Biochem. 369:248-255, 2007; Mirsa et al., Bioorg. Med. Chem. Lett. 17:3749-3753, 2007; and Choithani et al., Methods Mol Biol. 381:133-163, 2007).

[0083] Traditional conjugation techniques, particularly those involving amine groups, have relied on homobifunctional linkages. One of the most common techniques has been the use of bisaldehydes, such as glutaraldehyde. Disuccinimidyl substrate (DSS), available commercially as Synthetic Nucleic Acid Probe (SNAP) technology from Syngene (Frederick, MD), or the reagent p-phenylenediisothiocyanate, can also be used to generate covalent bonds between nucleic acids and therapeutic nanoparticles. N,N'-o-phenylenedimaleimide can be used to crosslink thiol groups. With all homobifunctional crosslinkers, the nucleic acid is first activated and then added to the therapeutic nanoparticles (see, e.g., Swami et al., Int. J. Pharm. 374:125-138, 2009; Todt et al., Methods Mol. Biol. 529:81-100, 2009; and Limanskii, Biofizika 51:225-235, 2006).

[0084] Heterobifunctional linkers can also be used to link nucleic acids to therapeutic nanoparticles. For example, N-succinimidyl-3-(2-pyridyldithio)proprionate (SPDP) is first linked to primary amines to generate dithiol-modified compounds. This can then react with thiols to exchange pyridylthiols for incoming thiols (see, for example, Nostrum et al., J. Control Release 15;153(1):93-102, 2011, and Berthold et al., Bioconjug. Chem. 21:1933-1938, 2010).

[0085] An alternative approach to thiol utilization is the thiol exchange reaction. When thiolated nucleic acids are introduced onto disulfide therapeutic nanoparticles, a disulfide exchange reaction occurs, thereby covalently linking the nucleic acid to the therapeutic nanoparticles via disulfide bonds. Numerous potential crosslinking chemistries are available for heterobifunctional crosslinking of amines and thiols. These procedures have generally been used with thiolated nucleotides. Commonly used reagents have been NHS (N-hydroxysuccinimide ester), MBS (m-maleimidobenzoyl-N-succinimide ester), and SPDP (pyridyl disulfide-based systems). Commonly used heterobifunctional linkers rely on aminated nucleic acids. Additional methods for covalently linking nucleic acids to therapeutic nanoparticles are known in the art.

[0086] nanoparticles In some embodiments, the therapeutic nanoparticles may have a diameter of about 2 nm to about 200 nm (e.g., about 10 nm to about 30 nm, about 5 nm to about 25 nm, about 10 nm to about 25 nm, about 15 nm to about 25 nm, about 20 nm to about 25 nm, about 25 nm to about 50 nm, about 50 nm to about 200 nm, about 70 nm to about 200 nm, about 80 nm to about 200 nm, about 100 nm to about 200 nm, about 140 nm to about 200 nm, and about 150 nm to about 200 nm).

[0087] In some embodiments, the therapeutic nanoparticles can have a diameter that is about 18% to about 28% (e.g., about 18% to about 23%, about 20% to about 23%, about 23% to about 25%, about 23% to about 28%) larger than the diameter of nanoparticles that do not contain a radiolabel. In some embodiments, the therapeutic nanoparticles can have a diameter that is about 23% larger than the diameter of nanoparticles that do not contain a radiolabel. In some embodiments, the therapeutic nanoparticles can accumulate in the metastatic tissue of a subject at a rate similar to that of metastatic-targeted nanoparticles that do not contain a radiolabel. In some embodiments, the therapeutic nanoparticles exhibit approximately equivalent accumulation in the metastatic tissue of a subject compared to metastatic-targeted nanoparticles that do not contain a radiolabel.

[0088] In some embodiments, therapeutic nanoparticles provided herein can be spherical or ellipsoidal, or can have an amorphous shape. In some embodiments, therapeutic nanoparticles provided herein can have a diameter (between any two points on the outer surface of a therapeutic nanoparticle) of about 2 nm to about 200 nm (e.g., about 10 nm to about 200 nm, about 2 nm to about 30 nm, about 5 nm to about 25 nm, about 10 nm to about 25 nm, about 15 nm to about 25 nm, about 20 nm to about 25 nm, about 50 nm to about 200 nm, about 70 nm to about 200 nm, about 80 nm to about 200 nm, about 100 nm to about 200 nm, about 140 nm to about 200 nm, and about 150 nm to about 200 nm). In some embodiments, therapeutic nanoparticles having a diameter of about 2 nm to about 30 nm localize to a subject's lymph nodes. In some embodiments, therapeutic nanoparticles having a diameter between about 40 nm and about 200 nm localize to the liver.

[0089] In some embodiments, the therapeutic nanoparticles can be magnetic (e.g., comprise a core of a magnetic material). In some embodiments, any of the therapeutic nanoparticles described herein can comprise a core of a magnetic material (e.g., therapeutic magnetic nanoparticles). In some embodiments, the therapeutic nanoparticles can comprise an iron oxide core. In some embodiments, the magnetic material or particle can comprise a diamagnetic, paramagnetic, superparamagnetic, or ferromagnetic material that responds to a magnetic field. Non-limiting examples of therapeutic magnetic nanoparticles include a core of a magnetic material comprising a metal oxide selected from the group: magnetite; ferrite (e.g., manganese, cobalt, and nickel ferrites); Fe(II) oxide; and hematite, and metal alloys thereof. The core of a magnetic material can be formed by converting a metal salt to a metal oxide using methods known in the art (e.g., Kieslich et al., Inorg. Chem. 2011). In some embodiments, the nanoparticles comprise cyclodextrin, gold, or quantum dots. Non-limiting examples of methods that can be used to produce therapeutic magnetic nanoparticles are described in Medarova et al., Methods Mol. Biol. 555:1-13, 2009; and Medarova et al., Nature Protocols 1:429-431, 2006. Additional magnetic materials and methods for producing magnetic materials are known in the art. In some embodiments of the methods described herein, the position or localization of the therapeutic magnetic nanoparticles can be imaged in a subject (e.g., imaged in a subject after administration of one or more doses of therapeutic magnetic nanoparticles).

[0090] In some embodiments, the therapeutic nanoparticles described herein do not include magnetic materials. In some embodiments, the therapeutic nanoparticles may include a core that comprises, in part, a polymer (e.g., poly(lactic-co-glycolic acid)). One skilled in the art will appreciate that nanoparticles can be prepared using any number of materials known in the art, including, but not limited to, gums (e.g., acacia, guar), chitosan, gelatin, sodium alginate, and albumin. Additional polymers that can be used to produce the therapeutic nanoparticles described herein are known in the art. For example, polymers that can be used to generate therapeutic nanoparticles include, but are not limited to, cellulosics, poly(2-hydroxyethyl methacrylate), poly(N-vinylpyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol), poly(acrylic acid), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polylactide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), polyanhydrides, polyorthoesters, polycyanoacrylates, and polycaprolactones.

[0091] Those skilled in the art will understand that the materials used in nanoparticle compositions, methods for preparation, coating, and methods for controlling nanoparticle size can vary substantially. However, these methods are well known to those skilled in the art. Important issues include the biodegradability, toxicity profile, and pharmacokinetics / pharmacodynamics of nanoparticles. The composition and / or size of nanoparticles are important determinants of their biological fate. For example, larger nanoparticles are generally taken up and degraded by the liver, whereas smaller nanoparticles (<30 nm in diameter) generally circulate for long periods (blood half-lives in humans that can exceed 24 hours) and accumulate in the interstitium of organs with high vascular permeability, such as lymph nodes and tumors.

[0092] polymer coating The therapeutic nanoparticles described herein include a polymer coating on a core magnetic material (e.g., on the surface of the magnetic material). The polymer material can be suitable for binding or coupling one or more biological agents (e.g., any of the nucleic acids described herein). The one or more biological agents (e.g., nucleic acids, fluorophores, or targeting peptides) can be immobilized on the polymer coating by chemical coupling (covalent bonding).

[0093] In some embodiments, therapeutic nanoparticles are formed by a method that includes coating a core of magnetic material with a polymer that is relatively stable in water, hi some embodiments, therapeutic nanoparticles are formed by a method that includes coating a magnetic material with a polymer or absorbing a magnetic material into a thermoplastic polymer resin having reducing groups thereon. Coatings can also be applied to magnetic materials using methods described in U.S. Pat. Nos. 5,834,121, 5,395,688, 5,356,713, 5,318,797, 5,283,079, 5,232,789, 5,091,206, 4,965,007, 4,774,265, 4,770,183, 4,654,267, 4,554,088, 4,490,436, 4,336,173, 4,421,660; and WO 10 / 111066, the disclosures of each of which are incorporated herein by reference.

[0094] Methods for synthesizing iron oxide nanoparticles include, for example, physical and chemical methods. For example, iron oxide can be synthesized by dissolving Fe in an aqueous solution. 2+ Salt and Fe 3+ They can be prepared by co-precipitation of salts. The resulting cores consist of magnetite (Fe3O4), maghemite (γ-Fe2O3), or a mixture of both. The anionic salt content (chloride, nitrate, sulfate, etc.), Fe2+ and Fe 3+ The ratio of , pH, and ionic strength of the aqueous solution all play a role in controlling size. It is important to conduct the reaction in an oxygen-free environment under an inert gas, such as nitrogen or argon, to prevent oxidation of the synthesized nanoparticles and preserve their magnetic properties. Coating materials can be added during the coprecipitation process to prevent the iron oxide nanoparticles from agglomerating into fine particles. Those skilled in the art will appreciate that any number of surface coating materials known in the art can be used to stabilize iron oxide nanoparticles, including synthetic and natural polymers, such as polyethylene glycol (PEG), dextran, polyvinylpyrrolidone (PVP), fatty acids, polypeptides, chitosan, and gelatin, among others.

[0095] For example, U.S. Pat. No. 4,421,660 discloses that polymer-coated particles of inorganic materials are conventionally prepared by (1) treating an inorganic solid with an acid, a combination of an acid and a base, an alcohol, or a polymer solution, (2) dispersing an addition-polymerizable monomer in an aqueous dispersion of the treated inorganic solid, and (3) subjecting the resulting dispersion to emulsion polymerization conditions. (Column 1, lines 21-27) U.S. Pat. No. 4,421,660 also discloses a method for coating inorganic nanoparticles with a polymer, comprising the steps of (1) emulsifying a hydrophobic, emulsion-polymerizable monomer in an aqueous colloidal dispersion of discrete particles of the inorganic solid, and (2) subjecting the resulting emulsion to emulsion polymerization conditions to form a stable, fluid aqueous colloidal dispersion of inorganic solid particles dispersed in a matrix of a water-insoluble polymer of the hydrophobic monomer. (Column 1, lines 42-50)

[0096] Alternatively, polymer-coated magnetic materials that meet the starting size requirements can be commercially available. For example, commercially available ultra-small superparamagnetic iron oxide nanoparticles include NC100150 Injection (Nycomed Amersham, Amersham Health) and Ferumoxytol (AMAG Pharmaceuticals, Inc.).

[0097] Suitable polymers that can be used to coat the magnetic core include, but are not limited to, polystyrene, polyacrylamide, polyetherurethane, polysulfone, fluorinated or chlorinated polymers such as polyvinyl chloride, polyethylene, and polypropylene, polycarbonate, and polyester. Further examples of polymers that can be used to coat the magnetic core include polyolefins such as polybutadiene, polydichlorobutadiene, polyisoprene, polychloroprene, polyvinylidene halide, polyvinylidene carbonate, and polyfluorinated ethylene. Numerous copolymers including styrene / butadiene, alpha-methylstyrene / dimethylsiloxane, or other polysiloxanes can also be used to coat the magnetic core (e.g., polydimethylsiloxane, polyphenylmethylsiloxane, and polytrifluoropropylmethylsiloxane). Additional polymers that can be used to coat the core of magnetic material include polyacrylonitrile or acrylonitrile-containing polymers such as polyalpha-acrylonitrile copolymers, alkyd or terpenoid resins, and polyalkylene polysulfonates. In some embodiments, the polymer coating is dextran.

[0098] Pharmaceutical Composition Also provided herein are pharmaceutical compositions comprising the therapeutic nanoparticles described herein. Two or more (e.g., two, three, or four) of any type of therapeutic nanoparticles described herein can be present in the pharmaceutical composition in any combination. The pharmaceutical composition can be formulated by any method known in the art.

[0099] Pharmaceutical compositions are formulated to be compatible with their intended route of administration (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal). In some embodiments, the compositions provided herein may contain a pharmaceutically acceptable diluent (e.g., a sterile diluent). In some embodiments, the pharmaceutically acceptable diluent may be sterile water, sterile saline, fixed oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents, antibacterial or antifungal agents such as benzyl alcohol or methylparaben, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like, antioxidants such as ascorbic acid or sodium bisulfite, chelating agents such as ethylenediaminetetraacetic acid, buffers such as acetates, citrates, or phosphates, and isotonic agents such as sugars (e.g., dextrose), polyhydric alcohols (e.g., mannitol or sorbitol), or salts (e.g., sodium chloride), or any combination thereof.

[0100] In some embodiments, the pharmaceutical compositions provided herein may include a pharmaceutically acceptable carrier. Liposomal suspensions may also be used as pharmaceutically acceptable carriers (see, e.g., U.S. Pat. No. 4,522,811). The composition preparations may be formulated and enclosed in ampoules, disposable syringes, or multiple-dose vials. Where necessary (e.g., as in injection formulations), proper fluidity may be maintained, for example, by the use of a coating such as lecithin or a surfactant. Absorption of therapeutic nanoparticles can be prolonged by including an absorption-delaying agent (e.g., aluminum monostearate and gelatin). Alternatively, controlled release can be achieved by implants and microencapsulated delivery systems, which may include biodegradable, biocompatible polymers (e.g., ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid; Alza Corporation and Nova Pharmaceutical, Inc.).

[0101] Compositions comprising one or more of any of the therapeutic nanoparticles described herein can be formulated for parenteral (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal) administration in dosage unit form (i.e., physically discrete units containing a predetermined amount of active compound for ease of administration and uniformity of dosage). In some embodiments, compositions comprising one or more of any of the therapeutic nanoparticles described herein can be formulated into a dosage form that is an injectable, tablet, lyophilized powder, suspension, or any combination thereof.

[0102] The toxicity and therapeutic effect of a composition can be determined by standard pharmaceutical procedures in cell cultures or experimental animals (e.g., monkeys). For example, the LD50 (the dose lethal to 50% of the population) and ED50 (the dose therapeutically effective in 50% of the population) can be determined; the therapeutic index is the ratio of LD50:ED50. Agents that exhibit a high therapeutic index are preferred. If an agent exhibits undesirable side effects, care should be taken to minimize potential damage (i.e., reduce undesirable side effects). Toxicity and therapeutic effect can be determined by other standard pharmaceutical procedures.

[0103] Data obtained from cell culture assays and animal studies may be used in formulating an appropriate dosage of any given agent for use in a subject (e.g., a human). A therapeutically effective amount of one or more (e.g., one, two, three, or four) therapeutic nanoparticles (e.g., any of the therapeutic nanoparticles described herein) is an amount that reduces or stabilizes the size of metastatic tumors in the lymph nodes of a subject, reduces the growth rate of metastatic tumors in the lymph nodes of a subject, reduces the severity, frequency, and / or duration of one or more symptoms of metastatic cancer in lymph nodes of a subject (e.g., a human), or reduces the number of symptoms of metastatic cancer in lymph nodes of a subject (e.g., a human) (e.g., compared to a control subject with the same disease but not treated, or a different treatment, or the same subject prior to treatment).

[0104] The efficacy and dosing of any of the therapeutic nanoparticles described herein can be determined by a medical practitioner using methods known in the art and by observation of one or more symptoms of metastatic cancer in lymph nodes in a subject (e.g., a human). Certain factors may affect the dosage and timing required to effectively treat a subject (e.g., the severity of the subject's disease or disorder, previous treatments, general health and / or age, and the presence of other diseases).

[0105] Exemplary doses include milligram or microgram amounts of any of the therapeutic nanoparticles described herein per kilogram of subject body weight. For example, in some embodiments, therapeutic nanoparticles can be administered to a subject at a dose of less than about 0.020 mg / kg (e.g., about 0.001 mg / kg to about 0.005 mg / kg, about 0.005 to about 0.010 mg / kg, about 0.010 mg / kg to about 0.015 mg / kg, about 0.011 mg / kg to about 0.015 mg / kg, about 0.012 mg / kg to about 0.015 mg / kg, about 0.013 mg / kg to about 0.015 mg / kg, about 0.012 mg / kg to about 0.016 mg / kg, about 0.013 mg / kg to about 0.017 mg / kg, about 0.013 mg / kg to about 0.018 mg / kg, or about 0.015 mg / kg to about 0.020 mg / kg). In some embodiments, the therapeutic nanoparticles may be administered to a subject at a dose that is less than about 0.014 mg / kg. In some embodiments, the therapeutic nanoparticles may be administered to a subject at a dose that is less than about 0.014 mg / kg for imaging, detecting, diagnosing, and / or monitoring metastatic cancer tissue in a subject.

[0106] In some embodiments, the therapeutic nanoparticles are administered at a concentration of about 1 mg / kg to about 10 mg / kg (e.g., about 1 mg / kg to about 5 mg / kg, about 1 to about 7 mg / kg, about 2 mg / kg to about 7 mg / kg, about 2 mg / kg to about 8 mg / kg, about 2 mg / kg to about 9 mg / kg, about 2 mg / kg to about 10 mg / kg, about 3 mg / kg to about 5 mg / kg, about 3 mg / kg to about 6 mg / kg, about 3 mg / kg to about 7 mg / kg, about 3 mg / kg to about 8 mg / kg, about 3 mg / kg to about 9 mg / kg, about 3 mg / kg to about 10 mg / kg, about 4 mg / kg to about 5 mg / kg, about 4 mg / kg to about 6 mg / kg, about 4 mg / kg to about 4 mg / kg, The therapeutic nanoparticles may be administered to a subject at a dose ranging from about 7 mg / kg, about 4 mg / kg to about 8 mg / kg, about 4 mg / kg to about 9 mg / kg, about 4 mg / kg to about 10 mg / kg, about 5 mg / kg to about 6 mg / kg, about 5 mg / kg to about 7 mg / kg, about 5 mg / kg to about 8 mg / kg, about 5 mg / kg to about 9 mg / kg, about 5 mg / kg to about 10 mg / kg, about 6 mg / kg to about 7 mg / kg, about 6 mg / kg to about 8 mg / kg, about 6 mg / kg to about 9 mg / kg, about 6 mg / kg to about 10 mg / kg, about 7 mg / kg to about 8 mg / kg, about 7 mg / kg to about 9 mg / kg, or about 7 mg / kg to about 10 mg / kg. In some embodiments, the therapeutic nanoparticles may be administered to a subject at a dose of about 5 mg / kg to about 7 mg / kg. In some embodiments, the therapeutic nanoparticles can be administered to a subject at a dose of about 5 mg / kg to less than about 7 mg / kg to treat metastatic cancer and / or reduce cellular invasion or metastasis in the subject.

[0107] While these dosages cover a certain range, those skilled in the art will understand that therapeutic agents, including the therapeutic nanoparticles described herein, vary in potency, and effective amounts can be determined by methods known in the art. Typically, a relatively low dose is administered initially, and the attending medical professional (for therapeutic applications) or researcher (for work still in the development stage) can then gradually increase the dose until an appropriate response is obtained. Furthermore, it will be understood that the specific dosage level for any particular subject will depend on a variety of factors, including the activity of the particular compound used, the subject's age, weight, general health, sex, and diet, the time of administration, the route of administration, the rate of excretion, and the in vivo half-life of the therapeutic nanoparticles.

[0108] The pharmaceutical compositions can be included in a kit, container, pack, or dispenser together with instructions for administration.

[0109] Treatment method The therapeutic nanoparticles described herein have been found to reduce cancer cell invasion and inhibit cancer cell metastasis. In light of this discovery, provided herein are methods for reducing cancer cell invasion or metastasis in a subject, methods for treating metastatic cancer in a lymph node of a subject, and methods for delivering nucleic acids to cells present in a lymph node of a subject. Specific embodiments and various aspects of these methods are described below.

[0110] Methods for treating metastatic cancer A metastatic cancer is a cancer that originates from cancer cells of a primary tumor that have migrated to a different tissue within a subject. In some embodiments, cancer cells from a primary tumor may migrate to a different tissue within a subject by traveling through the subject's bloodstream or lymphatic system. In some embodiments, a metastatic cancer is a metastatic cancer that is present in a lymph node within a subject.

[0111] The symptoms of metastatic cancer experienced by a subject depend on the site of metastatic tumor formation. Non-limiting symptoms of metastatic cancer in a subject's brain include: headache, dizziness, and blurred vision. Non-limiting symptoms of metastatic cancer in a subject's liver include: weight loss, fever, nausea, loss of appetite, abdominal pain, abdominal fluid (ascites), jaundice, and leg swelling. Non-limiting symptoms of metastatic cancer to a subject's bones include: pain and bone breakage if there is only minor or no injury. Non-limiting symptoms of metastatic cancer to a subject's lungs include: non-productive cough, cough that brings up blood, chest pain, and shortness of breath.

[0112] Metastatic cancer can be diagnosed in a subject by a medical professional (e.g., a doctor, a physician's assistant, a nurse, or a laboratory technician) using methods known in the art.For example, metastatic cancer can be diagnosed in a subject in part by observing or detecting at least one symptom of metastatic cancer in the subject (e.g., any of the symptoms listed above).Metastatic cancer can also be diagnosed in a subject using various imaging techniques (e.g., alone or in combination with observing one or more symptoms of metastatic cancer in the subject).For example, the presence of metastatic cancer (e.g., metastatic cancer in lymph nodes) can be detected in a subject using computed tomography, magnetic resonance imaging, positron emission tomography, and X-ray.Metastatic cancer (e.g., metastatic cancer in lymph nodes) can also be diagnosed by performing a tissue biopsy from the subject (e.g., a lymph node biopsy from the subject).

[0113] Metastatic tumors can form in a variety of different tissues in a subject, including, but not limited to, the brain, lung, liver, bone, peritoneum, adrenal gland, skin, and muscle. The primary tumor can be any type of cancer, including, but not limited to, breast cancer, colon cancer, kidney cancer, lung cancer, skin cancer, ovarian cancer, pancreatic cancer, rectal cancer, stomach cancer, thyroid cancer, or uterine cancer.

[0114] Any one or more of the therapeutic nanoparticles described herein may be administered to a subject with metastatic cancer. One or more therapeutic nanoparticles can be administered to the subject at a medical facility (e.g., a hospital or clinic) or an assisted care facility. In some embodiments, the subject has previously been diagnosed with cancer (e.g., a primary cancer). In some embodiments, the subject has previously been diagnosed with metastatic cancer (e.g., cancer that has spread to lymph nodes). In some embodiments, the subject has already received therapeutic treatment for the primary cancer. In some embodiments, the subject's primary tumor has been surgically removed prior to treatment with one of the therapeutic nanoparticles described herein. In some embodiments, at least one lymph node has been removed from the subject prior to treatment with one of the therapeutic nanoparticles described herein. In some embodiments, the subject may be in remission from cancer.

[0115] In some embodiments, administration of at least one therapeutic nanoparticle results in a decrease (e.g., a significant or observable decrease) in the size of metastatic tumors present in lymph nodes, stabilization of the size of metastatic tumors present in lymph nodes (e.g., no significant or observable change in size), or a decrease (e.g., a detectable or observable decrease) in the growth rate of metastatic tumors present in the subject's lymph nodes. Medical professionals can monitor the size and / or changes in size of metastatic tumors present in the subject's lymph nodes using a variety of different imaging techniques, including, but not limited to, computed tomography, magnetic resonance imaging, positron emission tomography, and X-ray. For example, the size of metastatic tumors present in the subject's lymph nodes can be determined before and after treatment to determine whether there has been a decrease or stabilization in the size of the subject's metastatic tumor in response to the treatment. The growth rate of metastatic tumors in the subject's lymph nodes can be compared to the growth rate of metastatic tumors in other subjects or subject populations that have not received treatment or have received a different treatment. A reduction in the growth rate of metastatic tumors in a subject's lymph nodes can also be determined by comparing the growth rate of metastatic tumors in the lymph nodes both before and after therapeutic treatment (e.g., treatment with any of the therapeutic nanoparticles described herein). In some embodiments, visualization of metastatic tumors (e.g., metastatic tumors in lymph nodes) can be performed using imaging techniques that utilize labeled probes or molecules that specifically bind to cancer cells of metastatic tumors (e.g., labeled antibodies that selectively bind to epitopes present on the surface of primary cancer cells).

[0116] In some embodiments, administering at least one therapeutic nanoparticle to a subject results in a reduced risk of developing an additional metastatic tumor in a subject who already has at least one metastatic tumor (e.g., a subject who already has a metastatic tumor in a lymph node) (e.g., compared to the rate of developing an additional metastatic tumor in subjects who already have a similar metastatic tumor but who are not being treated or are receiving an alternative treatment). The reduced risk of developing an additional metastatic tumor in a subject who already has at least one metastatic tumor can also be compared to the risk of developing an additional metastatic tumor in a population of subjects who are not being treated or are receiving an alternative form of cancer treatment.

[0117] In some embodiments, administering a therapeutic nanoparticle to a subject reduces the risk of developing metastatic cancer (e.g., metastatic cancer in lymph nodes) in a subject who has (e.g., has been diagnosed with) a primary cancer (e.g., primary breast cancer) (e.g., compared to the rate of developing metastatic cancer in subjects with a similar primary cancer who are not being treated or who are receiving alternative treatments). The reduced risk of developing metastatic tumors in subjects with a primary cancer can also be compared to the rate of formation of metastatic cancer in a population of subjects who are not being treated or who are receiving alternative forms of cancer treatment.

[0118] Medical professionals can also evaluate the effectiveness of a therapeutic treatment for metastatic cancer (for example, metastatic cancer in a subject's lymph nodes) by observing a decrease in the number of symptoms of metastatic cancer in the subject, or by observing a decrease in the severity, frequency, and / or duration of one or more symptoms of metastatic cancer in the subject.Various symptoms of metastatic cancer are known in the art and are described herein.Non-limiting examples of symptoms of metastatic cancer in lymph nodes include: painful lymph nodes, swollen lymph nodes, loss of appetite, and weight loss.

[0119] In some embodiments, administering may result in an increased (e.g., a significant increase) probability of survival of the subject's primary or metastatic cancer (e.g., compared to a population of subjects with a similar primary or metastatic cancer but receiving a different or no therapeutic treatment). In some embodiments, administering may result in an improved prognosis of the subject with a primary or metastatic cancer (e.g., compared to a population of subjects with a similar primary or metastatic cancer but receiving a different or no therapeutic treatment).

[0120] Methods for reducing cancer cell invasion or metastasis Also provided are methods for reducing (e.g., significantly or observably reducing) cancer cell invasion or metastasis in a subject, comprising administering to the subject at least one therapeutic nanoparticle described herein in an amount sufficient to reduce cancer cell invasion or metastasis in the subject.

[0121] In some embodiments of these methods, the metastasis of cancer cells is from a primary tumor (e.g., any of the primary tumors described herein) to a secondary tissue (e.g., a lymph node) in the subject. In some embodiments of these methods, the metastasis of cancer cells is from a lymph node to a secondary tissue (e.g., any of the secondary tissues described herein) in the subject.

[0122] In some embodiments, cancer cell invasion is the movement of cancer cells into tissues adjacent to the primary tumor. In some embodiments, cancer cell invasion is the movement of cancer cells from the primary tumor into the lymphatic system. In some embodiments, cancer cell invasion is the movement of metastatic cancer cells present in lymph nodes into the lymphatic system, or the movement of metastatic cancer cells present in secondary tissues into adjacent tissues in a subject.

[0123] The invasion of cancer cells in a subject can be evaluated or monitored by visualization using any of the imaging techniques described herein. For example, one or more tissues of a subject with cancer or metastatic cancer can be visualized at two or more time points (e.g., immediately after the cancer is diagnosed and at a later time point). In some embodiments, the reduction of cancer cell invasion in a subject can be detected by observing the reduction of the spread of primary tumor through a specific tissue in the subject (when the spread of primary tumor is assessed by imaging techniques known in the art or described herein). In some embodiments, the reduction of cancer cell invasion can be detected by a decrease in the number of circulating primary cancer cells or circulating metastatic cancer cells in the blood or lymph of the subject.

[0124] The metastasis of cancer cells can be detected by using any of the methods described herein or known in the art.For example, the success of reducing the metastasis of cancer cells can be observed as a reduction in the incidence of further metastatic tumors in subjects who already have at least one metastatic tumor (for example, subjects who already have metastatic tumors in lymph nodes) (for example, compared to the incidence of further metastatic tumors in subjects or subject populations who already have similar metastatic tumors but have not been treated or have received alternative treatment).The success of reducing the metastasis of cancer cells can also be observed as a reduction in the risk of developing at least one metastatic cancer (for example, metastatic cancer to lymph nodes) in subjects who have (for example, been diagnosed with) primary cancer (for example, primary breast cancer) (for example, compared to the risk of developing metastatic cancer in subjects or subject populations who have similar primary cancer but have not been treated or have received alternative treatment).

[0125] Methods for detecting, diagnosing, and / or monitoring metastatic cancer tissue Also provided herein is a method for detecting, diagnosing, and / or monitoring metastatic cancer tissue in a subject, the method comprising administering to a subject having metastatic cancer tissue any of the therapeutic nanoparticles disclosed herein and imaging the therapeutic nanoparticles.

[0126] In some embodiments of these methods, the therapeutic nanoparticles are administered in an amount sufficient to image the therapeutic nanoparticles in the subject. In some embodiments, the amount of therapeutic nanoparticles sufficient to detect, diagnose, and / or monitor metastatic cancer tissue in a subject is less than about 0.020 mg / kg (e.g., about 0.001 mg / kg to about 0.005 mg / kg, about 0.005 to about 0.010 mg / kg, about 0.010 mg / kg to about 0.015 mg / kg, about 0.011 mg / kg to about 0.015 mg / kg, about 0.012 mg / kg to about 0.015 mg / kg, about 0.013 mg / kg to about 0.015 mg / kg, about 0.012 mg / kg to about 0.016 mg / kg, about 0.013 mg / kg to about 0.017 mg / kg, about 0.013 mg / kg to about 0.018 mg / kg, or about 0.015 mg / kg to about 0.020 mg / kg). In some embodiments, the amount of therapeutic nanoparticles sufficient to detect, diagnose, and / or monitor metastatic cancer tissue in a subject is less than about 0.001 mg / kg. In some embodiments, the amount of therapeutic nanoparticles sufficient to detect, diagnose, and / or monitor metastatic cancer tissue in a subject is less than about 0.014 mg / kg. In some embodiments, the amount of therapeutic nanoparticles sufficient to detect, diagnose, and / or monitor metastatic cancer tissue in a subject does not induce adverse drug reactions in the subject.

[0127] In some embodiments, imaging is performed by magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), computed tomography (CT), or any combination thereof. In some embodiments, imaging is performed by PET-MRI. In some embodiments, the therapeutic nanoparticles of the present disclosure can accumulate in metastatic cancer tissue and therefore can be effective in highlighting metastatic tissue when imaged (e.g., by PET or PET-MRI).

[0128] Dosage, Administration, and Compositions In any of the methods described herein, the therapeutic nanoparticles can be administered by a medical professional (e.g., a doctor, physician's assistant, nurse, or laboratory or clinic personnel), the subject (i.e., self-administered), or a friend or family member of the subject. Administering can occur in a clinical setting (e.g., a clinic or hospital), an assisted living facility, or a pharmacy.

[0129] In some embodiments of any of the methods described herein, the therapeutic nanoparticles are administered to a subject diagnosed with cancer (e.g., having primary or metastatic cancer). In some embodiments, the subject has been diagnosed with breast cancer (e.g., metastatic breast cancer). In some non-limiting embodiments, the subject is male or female, an adult, adolescent, or child. The subject can experience one or more symptoms of cancer or metastatic cancer (e.g., metastatic cancer in lymph nodes). The subject can also be diagnosed with severe or advanced cancer (e.g., primary or metastatic cancer). In some embodiments, the subject has been identified as having a metastatic tumor present in at least one lymph node. In some embodiments, the subject may have already undergone lymphectomy and / or mastectomy.

[0130] In some embodiments of any of the methods described herein, the subject is administered at least one (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30) doses of a composition comprising at least one (e.g., 1, 2, 3, or 4) of any of the magnetic particles or pharmaceutical compositions described herein. In any of the methods described herein, at least one magnetic particle or pharmaceutical composition (e.g., any of the magnetic particles or pharmaceutical compositions described herein) may be administered to the subject intravenously, intraarterially, subcutaneously, intraperitoneally, or intramuscularly. In some embodiments, at least the magnetic particle or pharmaceutical composition is administered directly (injected) into the subject's lymph nodes.

[0131] In some embodiments, the subject is administered at least one therapeutic nanoparticle or pharmaceutical composition (e.g., any of the therapeutic nanoparticles or pharmaceutical compositions described herein) and at least one additional therapeutic agent. The at least one additional therapeutic agent is a chemotherapeutic agent (e.g., cyclophosphamide, mechlorethamine, chlorambucil, melphalan, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, barbican, paclitaxel, docetaxel, etoposide, teniposide, tafluposide, azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, thioguanine, bleomycin, carboplatin, cisplatin, oxaliplatin, bortezomib, carfilzomib, salinosporamide A, all-trans retinoic acid, vinblastine, vincristine ... desine, and vinorelbine) and / or analgesics (e.g., acetaminophen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, celecoxib, buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, proxyfen, tramedol).

[0132] In some embodiments, the at least one additional therapeutic agent and the at least one therapeutic nanoparticle (e.g., any of the therapeutic nanoparticles described herein) are administered in the same composition (e.g., the same pharmaceutical composition). In some embodiments, the at least one additional therapeutic agent and the at least one therapeutic nanoparticle are administered to a subject using different routes of administration (e.g., at least one additional therapeutic agent delivered by oral administration and at least one therapeutic nanoparticle delivered by intravenous administration).

[0133] In any of the methods described herein, at least one therapeutic nanoparticle or pharmaceutical composition (e.g., any of the therapeutic nanoparticles or pharmaceutical compositions described herein) and optionally at least one additional therapeutic agent may be administered to a subject at least once a week (e.g., once a week, twice a week, three times a week, four times a week, once a day, twice a day, or three times a day). In some embodiments, at least two different therapeutic nanoparticles are administered in the same composition (e.g., a liquid composition). In some embodiments, at least one therapeutic nanoparticle and at least one additional therapeutic agent are administered in the same composition (e.g., a liquid composition). In some embodiments, at least one therapeutic nanoparticle and at least one additional therapeutic agent are administered in two different compositions (e.g., a liquid composition comprising at least one therapeutic nanoparticle and a solid oral composition comprising at least one additional therapeutic agent). In some embodiments, at least one additional therapeutic agent is administered as a pill, tablet, or capsule. In some embodiments, at least one additional therapeutic agent is administered in a sustained release oral formulation.

[0134] In some embodiments, the one or more additional therapeutic agents may be administered to the subject prior to administration of at least one therapeutic nanoparticle or pharmaceutical composition (e.g., any of the therapeutic nanoparticles or pharmaceutical compositions described herein). In some embodiments, the one or more additional therapeutic agents may be administered to the subject after administration of at least one therapeutic nanoparticle or pharmaceutical composition (e.g., any of the magnetic particles or pharmaceutical compositions described herein). In some embodiments, the one or more additional therapeutic agents and at least one therapeutic nanoparticle or pharmaceutical composition (e.g., any of the therapeutic nanoparticles or pharmaceutical compositions described herein) are administered to the subject such that there is an overlap in the period of biological activity of the one or more additional therapeutic agents and the at least one therapeutic nanoparticle (e.g., any of the therapeutic nanoparticles or pharmaceutical compositions described herein) in the subject.

[0135] In some embodiments, a subject may be administered at least one therapeutic nanoparticle or pharmaceutical composition (e.g., any of the therapeutic nanoparticles or pharmaceutical compositions described herein) over an extended period of time (e.g., for a period of at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, or 10 years). A skilled medical professional can determine the length of the treatment period using any of the methods described herein (e.g., using methods described above and methods known in the art) to diagnose or track the effectiveness of the treatment. As described herein, a skilled medical professional can also alter (e.g., increase or decrease) the identity and number of therapeutic nanoparticles (and / or one or more additional therapeutic agents) administered to a subject, and adjust (e.g., increase or decrease) the dose or frequency of administration of at least one therapeutic nanoparticle (and / or one or more additional therapeutic agents) to a subject based on an assessment of the effectiveness of the treatment (e.g., using any of the methods described herein and known in the art). A skilled medical professional can further determine when to discontinue treatment (eg, when a subject's symptoms have significantly reduced).

[0136] Methods for preparing therapeutic nanoparticles Also provided herein is a method of preparing any of the therapeutic nanoparticles of the present disclosure, comprising preparing magnetic nanoparticles (e.g., via any one of the methods described elsewhere herein); covalently attaching a nucleic acid molecule to the magnetic nanoparticles; covalently attaching a chelator to the magnetic nanoparticles (MN) by reacting the magnetic nanoparticles with the chelator in a ratio of about 40:1 equivalents (eq.) (i.e., 40 equivalents of chelator to 1 equivalent of magnetic nanoparticles); 64 A solution of CuCl2 was added, 64 A method is provided that includes purifying a mixture of a solution of CuCl2 and magnetic nanoparticles to obtain therapeutic nanoparticles.

[0137] In some embodiments, the method comprises the step of: chelating a medicament comprising administering a medicament to a patient in need thereof, the method ... :MN, about 5:1 chelator eq.:MN to about 35:1 chelator eq.:MN, about 5:1 chelator eq.:MN to about 40:1 chelator eq.:MN, about 5:1 chelator eq.:MN to about 45:1 chelator eq.:MN, about 5:1 chelator eq.:MN to about 50:1 chelator eq.:MN, about 5:1 chelator eq.:MN to about 55:1 chelator eq.:MN, or about 5:1 chelator eq.:MN to about 60:1 chelator eq.:MN, about 10:1 chelator eq.:MN to about 12:1 chelator eq.:MN, about 10:1 chelator eq.:MN to approximately 15:1 chelator eq.:MN, approximately 10:1 chelator eq.:MN to approximately 20:1 chelator eq.:MN, approximately 10:1 chelator eq.:MN to approximately 25:1 chelator eq.:MN, approximately 10:1 chelator eq.:MN to approximately 30:1 chelator eq.:MN, approximately 10:1 chelator eq.:MN to approximately 35:1 chelator eq.:MN, approximately 10:1 chelator eq.:MN to approximately 40:1 chelator eq.:MN, approximately 10:1 chelator eq.:MN to approximately 45:1 chelator eq.:MN, approximately 10:1 chelator eq.:MN to approximately 50: 1 chelator eq.:MN, approximately 10:1 chelator eq.:MN to approximately 55:1 chelator eq.:MN, or approximately 10:1 chelator eq.:MN to approximately 60:1 chelator eq.:MN, approximately 15:1 chelator eq.:MN to approximately 20:1 chelator eq.:MN, approximately 15:1 chelator eq.:MN to approximately 25:1 chelator eq.:MN, approximately 15:1 chelator eq.:MN to approximately 30:1 chelator eq.:MN, approximately 15:1 chelator eq.:MN to approximately 35:1 chelator eq.:MN, approximately 15:1 chelator eq.:MN to approximately 40:1 chelator eq.:MN, about 15:1 chelator eq.:MN to about 45:1 chelator eq.:MN, about 15:1 chelator eq.:MN to about 50:1 chelator eq.:MN, about 15:1 chelator eq.:MN to about 55:1 chelator eq.:MN, or about 15:1 chelator eq.:MN to about 60:1 chelator eq.:MN, about 20:1 chelator eq.:MN to about 45:1 chelator eq.:MN, about 25:1 chelator eq.:MN to about 45:1 chelator eq.:MN, about 30:1 chelator eq.:MN to about 45:1 chelator eq.:MN, about 35:1 chelator eq.:MN to about 45:1 chelator eq.:MN, about 40:1 chelator eq. The method includes reacting the magnetic nanoparticles with a chelator in a ratio ranging from about 45:1 chelator eq.:MN, about 35:1 chelator eq.:MN to about 50:1 chelator eq.:MN, about 38:1 chelator eq.:MN to about 40:1 chelator eq.:MN, about 38:1 chelator eq.:MN to about 42:1 chelator eq.:MN, about 38:1 chelator eq.:MN to about 45:1 chelator eq.:MN, about 40:1 chelator eq.:MN to about 50:1 chelator eq.:MN, about 40:1 chelator eq.:MN to about 55:1 chelator eq.:MN, or about 40:1 chelator eq.:MN to about 60:1 chelator eq.:MN.

[0138] In some embodiments, covalently binding the chelator to the magnetic nanoparticles is carried out at a temperature of about 0°C to about 8°C (e.g., about 0°C to about 4°C, about 1°C to about 4°C, about 2°C to about 4°C, about 3°C ​​to about 4°C, about 2°C to about 6°C, about 3°C ​​to about 7°C, about 4°C to about 5°C, about 4°C to about 6°C, about 4°C to about 7°C, or about 4°C to about 8°C). In some embodiments, covalently binding the chelator to the magnetic nanoparticles is carried out at a temperature of about 4°C.

[0139] In some embodiments, these methods include: 64The method further includes heating the mixture of CuCl solution and magnetic nanoparticles at a temperature of about 40°C to about 65°C (e.g., about 40°C to about 65°C, about 45°C to about 65°C, about 50°C to about 65°C, about 55°C to about 65°C, about 56°C to about 65°C, about 57°C to about 65°C, about 58°C to about 65°C, about 59°C to about 65°C, about 58°C to about 62°C, about 59°C to about 61°C, about 58°C to about 63°C, about 59°C to about 63°C, about 59°C to about 60°C, about 60°C to about 61°C, or about 60°C to about 62°C). In some embodiments, the method further includes heating the mixture of CuCl solution and magnetic nanoparticles at a temperature of about 40°C to about 65°C (e.g., about 40°C to about 65°C, about 45°C to about 65°C, about 50°C to about 65°C, about 55°C to about 65°C, about 56°C to about 65°C, about 57°C to about 65°C, about 58°C to about 65°C, about 59°C to about 65°C, about 58°C to about 62°C, about 59°C to about 61°C, about 58°C to about 63°C, about 59°C to about 63°C, about 59°C to about 60°C, about 60°C to about 61°C, or about 60°C to about 62°C). 64 The method further includes heating the mixture of the solution of CuCl2 and the magnetic nanoparticles at a temperature of about 60°C.

[0140] In some embodiments, these methods include: 64 In some embodiments, these methods further include heating the mixture of CuCl2 solution and magnetic nanoparticles for about 10 minutes to about 30 minutes (e.g., about 10 minutes to about 20 minutes, about 11 minutes to about 21 minutes, about 12 minutes to about 22 minutes, about 13 minutes to about 23 minutes, about 14 minutes to about 24 minutes, about 15 minutes to about 25 minutes, about 16 minutes to about 26 minutes, about 13 minutes to about 20 minutes, about 15 minutes to about 20 minutes, about 15 minutes to about 22 minutes, about 18 minutes to about 20 minutes, about 18 minutes to about 22 minutes, about 19 minutes to about 21 minutes, about 19 minutes to about 23 minutes, about 20 minutes to about 25 minutes, or about 20 minutes to about 30 minutes). 64 The method further includes heating the mixture of the solution of CuCl2 and the magnetic nanoparticles for about 20 minutes.

[0141] In some embodiments, these methods do not expose the therapeutic nanoparticles to temperatures above about 65° C. In some embodiments, these methods do not expose the therapeutic nanoparticles to temperatures above about 60° C. In some embodiments, methods disclosed herein that involve the use of a chelator to associate a radiolabel with a therapeutic nanoparticle advantageously avoid harsh conditions that could potentially damage nucleic acid molecules (e.g., temperatures above about 60° C. for more than about 20 minutes). [Example]

[0142] Certain embodiments of the present disclosure are further described in the following examples, which do not limit the scope of any of the claimed embodiments.

[0143] [Example 1] In vitro testing of MN-anti-miR10b Dextran-coated therapeutic magnetic nanoparticles measuring 20-35 nm were functionalized with antisense locked nucleic acid (LNA) oligonucleotides targeting human miRNA-10b. The resulting therapeutic magnetic nanoparticles (MN) are hereafter referred to as "MN-anti-miR-10b." An in vitro cell-based assay to test these therapeutic magnetic nanoparticles was performed as described below.

[0144] Dextran-coated magnetic nanoparticles measuring 21.6 ± 0.5 nm were conjugated with an 8 ± 0.7 LNA antagomir targeting miRNA-10b (Exiqon, Woburn, MA) (Figure 1A). The MN-anti-miR10b therapeutic was functional in the human lymph node metastatic MDA-MB-231-luc-D3H2LN cell line (Perkin Elmer, Hopkinton, MA). Peak efficacy was achieved after 48 hours of incubation with MN-anti-miR10b (0.7 nmole ASO / ml), at which point there was a significant 86.3 ± 5.8% inhibition of target miRNA-10b compared to the inactive therapeutic MN-scr-miR functionalized with an unrelated oligonucleotide (Exiqon, Woburn, MA) (Figure 1B). These results demonstrated that this delivery method and therapeutic design could be used to highly efficiently inhibit miRNA-10b in tumor cells. To assess the therapeutic potential of this methodology, we investigated the effects of miR-10b inhibition on tumor cell apoptosis, proliferation, invasion and migration.

[0145] Inhibition of miR-10b by this therapeutic agent was found to result in significant apoptosis induction, growth inhibition, and reduction of invasion and migration (Figure 2). Additionally, a hypothesis was proposed that co-administration of a low dose of a cytotoxic chemotherapeutic agent (e.g., doxorubicin) amplifies the effect of the therapeutic agent, leading not only to tumor growth inhibition but also to regression and in some cases elimination of metastases. After combination treatment with this therapeutic agent (0.5 μM) and a low dose of doxorubicin (0.05 μM, <IC10), it was observed that tumor cells acquired a spindle shape, detached, and died (Figure 2A). This corresponded to significant induction of apoptosis (Figure 2B) and a decrease in proliferation (Figure 2C). Analysis of the effect of the combination treatment on the cell cycle revealed the potential mechanism underlying the synergistic effect observed between doxorubicin and the therapeutic agent. That is, polyploid formation and G2 / M arrest were induced by doxorubicin alone or in combination with the therapeutic agent (Figure 2D). This indicates that in the described scenario, doxorubicin inhibits the cell cycle and reduces the cell division rate of tumor cells, possibly ensuring a high local concentration of the therapeutic agent, thereby amplifying the apoptosis-promoting effect of the MN-anti-miR10b therapeutic agent. Consistent with this hypothesis, combination of low-dose doxorubicin and MN-anti-miR10b increased both the G1 pre-apoptotic cell and G2 / M arrested cell populations (Figure 2D). These studies demonstrated that combination of a low-dose cytocidal agent such as doxorubicin with miR-10b inhibition using the described therapeutic approach can mediate a clear effect on the phenotype of tumor cells, indicated by tumor cell death and loss of invasive properties at the endpoint. These results indicate that miR-10b is an essential metastamir for tumor cell survival and is similar to the mechanism of oncomir addiction. Further evidence for this hypothesis was obtained from experiments attempting to generate a miR-10b knockout subline from the MDA-MB-231-luc-D3H2LN cell line (Figure 3A). Within 24 hours after transfection with the knockout vector set (TALEN L+R), it was observed that the cells acquired a spindle-shaped three-dimensional structure and began to detach.By 72 hours after transfection, no viable cells were present (Fig. 3B). This latter result indicated that robust therapeutic effects could be achieved by treatment with higher doses of MN-anti-miR10b therapeutics alone, even in the absence of doxorubicin.

[0146] [Example 2] MN-anti-miR10b therapeutics can be delivered to distant metastatic tumor cells in vivo After demonstrating in vitro that targeting miR-10b with therapeutic nanoparticles and low-dose chemotherapeutic agents has significant implications in therapeutic scenarios, we determined whether the observed therapeutic effects could be achieved in vivo. The first step was to assess whether the therapeutic agents could be delivered to the target metastatic organs.

[0147] Fluorescently labeled therapeutic agents (labeled with Cy5.5 on MN) were injected into BALB / c mice orthotopically implanted with the murine mammary adenocarcinoma 4T1-luc2 cell line. In this model, orthotopically implanted tumors progress from local disease to lymph node, lung, and bone metastases by 3 weeks after tumor inoculation. Ex vivo near-infrared (NIRF) optical imaging performed 24 hours after intravenous injection of the therapeutic agent revealed uptake by metastatic lesions in lymph nodes, lungs, and bone (Figure 4A). Fluorescence microscopy confirmed widespread uptake by metastatic tumor cells in these organs (Figure 4B), supporting our hypothesis that the therapeutic agent can target cancers that have disseminated to distant organs as designed.

[0148] Low levels of MN-anti-miR10b accumulation were expected in organs of the reticuloendothelial system, where it was taken up by cells and rapidly degraded. The iron from the iron oxide core entered the endogenous iron pool, and the dextran nanoparticle coating was excreted by the kidney. In vivo imaging in animals with established brain metastases (Figure 4C) demonstrated uptake by metastatic lesions, indicating that the degree of blood-brain barrier disruption in this model was sufficient to allow delivery of therapeutic agents.

[0149] [Example 3] Treatment with MN-anti-miR10b can induce regression of lymph node metastases With an eye toward clinical application of this therapeutic approach, we aimed to induce regression of lymph node-metastatic breast cancer by combining low-dose doxorubicin (4 mg / kg weekly, i.p.) with MN-anti-miR10b therapeutic agents (15 mg / kg Fe, 10 mg / kg ASO weekly, i.v.). Specifically, 4–5 weeks after tumor inoculation, mice bearing orthotopic MDA-MB-231-luc-D3H2LN tumors underwent surgical removal of the primary tumor after confirmation of lymph node metastasis. This was done to better mimic the clinical scenario, as the current standard of care involves surgical removal of the primary tumor in patients with lymph node-metastatic breast cancer.

[0150] Treatment began the week of tumor removal. Experimental mice treated with MN-anti-miR10b and low-dose doxorubicin showed complete regression of lymph node metastases after 4 weeks of treatment (Figures 5A and 5B). In contrast, control mice showed progression of metastases. In experimental mice, complete regression of metastases was observed at week 4, at which point treatment was discontinued. By the end of the study, no recurrence was observed (Figures 5A and 5B).

[0151] Ex vivo analysis revealed the presence of lymph node metastases and metastatic dissemination to the lungs in control animals treated with PBS or inactive treatment, with or without doxorubicin (Figure 5C). Mice treated with MN-anti-miR10b alone had evidence of lymph node metastasis but not lung metastasis. In contrast, no gross lymph node or lung metastases were detected in mice treated with MN-anti-miR10b and doxorubicin (Figure 5C).

[0152] Treatment with MN-anti-miR10b and low-dose doxorubicin also resulted in significant improvements in body weight (Figure 5D) and survival rate (Figure 5E). Unlike the control group, none of the experimental animals (MN-anti-miR10b / doxorubicin) succumbed to cancer by 14 weeks after the start of treatment. Furthermore, the combination of doxorubicin and MN-anti-miR10b was superior to monotherapy with either drug (Figure 5A, 5B, 5C, and 5E).

[0153] By 15 weeks of treatment, differences between experimental and control animals were evident through simple anatomical observation. Control animals treated with MN-scr-miR and doxorubicin exhibited gross lymphadenopathy and cachexia. Experimental animals treated with MN-anti-miR10b and doxorubicin appeared healthy. Long-term observations indicated that remission of metastatic disease was durable, and that this treatment effectively cured the animals for their natural lifespan.

[0154] After efficacy was proven, the important issue of systemic toxicity had to be addressed. Analysis of a panel of blood chemistry markers, including indicators of nephrotoxicity, hepatotoxicity, etc., revealed no significant effects that could be attributed to the components of the therapeutic drug. Histopathological examination of major organs showed no gross tissue abnormalities.

[0155] [Example 4] Treatment with -MN-anti-miR10b can induce regression of distant metastases With particular reference to distant metastases, we combined low-dose doxorubicin (2 mg / kg weekly, i.p.) with MN-anti-miR10b treatment (15 mg / kg Fe, 10 mg / kg ASO weekly, i.v.) in immunocompetent mice (Balb / c) bearing orthotopic 4T1-luc2 breast tumors. In PBS-treated control mice, metastases progressed rapidly (Figures 6A and 6B), resulting in 100% animal mortality by week 5 (Figure 6C). In MN-scr-miR+dox-treated mice, metastases grew more slowly than in PBS controls (Figures 6A and 6B). Cancer mortality by week 7 was 80% (Figures 6A and 6B). In contrast, regression of distant metastases was observed by week 6 in MN-anti-miR10b+dox-treated mice (Figures 6A and 6B), at which point treatment was stopped (red arrows in Figure 6A). Animals remained metastasis-free throughout the course of the experiment. Regression was achieved in 65% of animals, while 35% of animals progressed due to inefficient inhibition of miR-10b in this group (Figure 6C). Macroscopic observation of the lungs after necropsy confirmed the absence of metastatic lesions in responders treated with MN-anti-miR10b + dox (Figure 6D).

[0156] [Example 5] nat / 64 Synthesis and characterization of Cu-MN-anti-miR10b Cu-64( 64 Anti-miR10b radiolabeled with Cu) and ultra-small iron oxide magnetic nanoparticles (MN), hereafter referred to as 64 The synthesis of "Cu-MN-anti-miR10b" began with the modification of MN, a 20 nm aminated dextran-coated iron oxide nanoparticle whose synthesis was previously reported (Yoo et al., 2014). The nanoparticles were optimized to enhance extravasation of the agent into the interstitium of tumors and metastatic lesions (Yoo et al., 2017a). MN nanoparticles were functionalized with the chelating ligand NODAGA by a coupling reaction between the amino group and the activated ester moiety of NODAGA (Figure 7). The NODAGA chelator is a highly stable ligand essential for preventing radiometal dissociation and subsequent retention in vivo. 64It has the ability to rapidly form Cu complexes. The number of NODAGA chelators per nanoparticle was quantified as 13±2. The Cu / nanoparticle ratio was nat After complexation with CuCl2, the valence number (A) was determined by ICP-MS to be 14 ± 1. Prior to in vivo testing, the nanoparticles were treated with SPDP and functionalized with anti-miR-10b antagomir via disulfide bonds. The number of antagomir per nanoparticle was characterized as 7.4 ± 0.2 according to previously described procedures (Yoo et al., 2014; Yoo et al., 2015). These therapeutic magnetic radiolabeled nanoparticles were produced and characterized as described below. All reactants and reagents were commercial grade and used without further purification. All solutions were prepared from MilliQ water. The metal-free buffer solution used for radiolabeling was prepared using Chelex 100 Resin (100-200 mesh, BioRad).

[0157] 64 To evaluate the in vivo biodistribution of Cu-MN-anti-miR10b, the development of an efficient labeling and purification method is necessary. Radiolabeling of MN-anti-miR10b was achieved in pH 6.8 acetate buffer at 60°C for 20 minutes. These conditions are favorable for labeling the NODAGA chelator while maintaining the integrity of the nanocarrier. After purification on a PD-10 column, 64 Cu-MN-anti-miR10b was obtained with a radiochemical purity of >99% and a specific activity of 7.1 mCi / mg iron (Figure 8A). Radiochemical identity was confirmed by size exclusion chromatography (Figure 8B). To further evaluate the effect of the presence of Cu-NODAGA chelate on nanoparticle size and target association, nat Cu-MN-anti-miR10b was synthesized. The size of the iron oxide crystal in the core was natThe measured values ​​were 4.71±0.24 nm for Cu-MN-anti-miR10b and 4.69±0.23 nm for MN. The surface modification did not cause any significant changes in the size and crystalline structure of the iron oxide core, as shown by transmission electron microscopy (TEM, Figure 8C). The dextran-coated functionalized nanoparticles nat The hydrodynamic diameter of Cu-MN-anti-miR10b was measured to be 27.1 ± 0.9 nm, which is 5.1 nm larger than that of parental MN. Introduction of Cu-NODAGA and anti-miR10b antigomil resulted in a 23% increase in hydrodynamic diameter (Figure 8D).

[0158] Cellular uptake, expressed as elemental iron per cell, was 9.33 ± 2.42 pg Fe / cell for MN-anti-miR10b; nat The Cu-MN-anti-miR10b treatment yielded 11.34 ± 3.62 pg Fe / cell, which was not significantly different (Figure 8E). Finally, we analyzed RNA-enriched cell extracts and compared the inhibition of miR10b by qRT-PCR. The expression levels of miR10b after treatment with MN-anti-miR10b or parental MN without antagomir were significantly higher than those after treatment with MN-anti-miR10b or parental MN without antagomir. nat miR10b expression after treatment with Cu-MN-anti-miR10b was completely inhibited ( Figure 8F ).

[0159] Synthesis of NODAGA-MN-anti-miR10b nat / 64The steps for the synthesis of Cu-MN-anti-miR10b are outlined in Figure 7. Amine-derivatized iron oxide nanoparticles (MNs) were prepared from dextran-coated iron oxide nanoparticles through modification with epichlorohydrin and ammonium hydroxide as previously described (Yoo et al., 2014). The nanoparticles were conjugated to NODAGA-NHS (Chematech, France) by reacting 1 ml of MN (87 μM, 10 mg Fe / ml, 54 NH2 / MN) with 2.54 mg of NODAGA-NHS ester (3.47 μmol, 40 eq. to MN) in 100 μl of PBS buffer (100 mM, pH 7.4). After the reaction was carried out overnight at 4 °C, the resulting NODAGA-conjugated nanoparticles (NODAGA-MN) were purified using a size-exclusion column (PD-10, GE Healthcare) eluted with nuclease-free PBS buffer. NODAGA-MN was treated with an excess of SPDP (250 eq.) for 4 hours at 4°C to form NODAGA-MN-SPDP, which was again purified on a size-exclusion column using nuclease-free PBS buffer as the eluent. The LNA antagomir, anti-miR10b, was synthesized and provided by Biospring (Frankfurt, Germany) according to GLP protocols. The anti-miR10b LNA antagomir was modified with a 5'-thiol-modifier C6 disulfide (5'-ThioMC6), which was used for conjugation with MN. The disulfide on the oligonucleotide was activated with 3% tris(2-carboxyethyl)phosphine hydrochloride (TCEP, Thermo Scientific Co.), purified by ammonium acetate / ethanol precipitation, and then conjugated to MN. After TCEP activation and purification, the oligo was dissolved in nuclease-free water and incubated with NODAGA-MN-SPDP overnight. The final product, NODAGA-MN-anti-miR10b, was prepared fresh before animal experiments.

[0160] non-radioactive nat Preparation of Cu-MN-anti-miR10b To evaluate the inhibitory effect of miR-10b in 4T1 cells, non-radioactive nat Cu-MN-anti-miR10b was prepared. 0.6 mg of NODAGA-MN-anti-miR10b was dispersed in acetate buffer (500 μL, pH 6.8, 0.1 M), followed by addition of CuCl (0.7 mg, 50 equivalents of Cu relative to NODAGA). 2+ The reaction mixture was stirred at 60°C for 20 min, and EDTA (100 μL, 100 mM, pH 7.4) was added to the mixture to remove unlabeled free Cu. 2+ After removal of ions, the product was purified on a size exclusion column (PD-10, GE Healthcare) using nuclease-free PBS buffer as the eluent. Fractions containing the desired product were combined and purified. nat The concentration of Cu-MN-anti-miR10b was determined by ICP-MS.

[0161] Radiolabeled MN-anti-miR10b ( 64 Preparation of Cu-MN-anti-miR10b Radiolabeling was performed according to commonly used procedures (Desogere et al., 2017). Briefly, 200 μg (as Fe) of NODAGA-MN-anti-miR10b in PBS was added to 500 μL of sodium acetate buffer (0.1 M, pH 6.8). 64 The reaction mixture was heated at 60 °C for 20 min and then purified on a size-exclusion column (PD-10 column) using nuclease-free PBS buffer as the eluent. 500 μL of the eluate was collected as fractions. The radiochemical purity of each fraction was controlled by iTLC (Agilent, iTLC-SG, Santa Clara, CA) using a radio-TLC imaging scanner (AR-2000, Eckert & Ziegler, Berlin, Germany) with EDTA solution (50 mM, pH 5) as the eluent. Fractions with a radiochemical purity of >99% were combined and used for in vivo animal experiments. 64The radiochemical identity of the final Cu-MN-anti-miR10b solution was confirmed by analytical HPLC (Agilent 1100 HPLC system, Santa Clara, CA) equipped with a size-exclusion column (TSK gel QC-PAK-300, homogeneous, 100% sodium phosphate, 0.1 M pH 7.4, 20 min) and a Caroll / Ramsey radioactivity detector with a silicone PIN photodiode and ultraviolet detection at 254 nm.

[0162] MN-anti-miR10b and nat Characterization of Cu-MN-anti-miR10b Copper and iron concentrations were determined by inductively coupled plasma mass spectrometry (ICP-MS) analysis (Agilent 8800-QQQ system, Santa Clara, CA). All samples were prepared by weight. Calibration standards were prepared by diluting certified copper and iron standards (1000 mg / L). Calibration curves were obtained from five standard solutions ranging from 0.1 to 400 ppb. Lutetium (1 ppm) was used as an external standard to ensure proper sample introduction. Hydrodynamic diameter and zeta potential were measured using a dynamic light scattering spectrometer (Zetasizer Nano, Malvern, UK), and iron oxide core size was determined using a transmission electron microscope (JEM 2100 TEM, Jeol, Tokyo, Japan). To quantify the number of NODAGA molecules per MN, the number of amines per MN was subtracted from the number of amines per MN after conjugation with NODAGA. The number of amines per MN was determined by the amount of pyridine-2-thione (343 nm, 8080 M) released from SPDP conjugated to amine groups in a 1:1 ratio. -1 cm -1 ) (ThermoFisher, Waltham, MA). Finally, the number of oligonucleotides per MN was determined spectrophotometrically using multiple standards with different concentrations. Briefly, MN-anti-miR10b and natCu-MN-anti-miR10b was purified using a magnetic column (MACS column, Miltenyi, Cambridge, MA) to remove unbound anti-miR10b oligo. Purified nanoparticles were assayed spectrophotometrically (Spectramax M2 microplate reader, Molecular Devices, Sunnyvale, CA) to determine iron concentration (410 nm) and oligo concentration (260 nm).

[0163] radioactive label 89 Preparation and characterization of Zr-MN-anti-miR10b 89 The steps for the synthesis of Zr-MN-anti-miR10b are outlined in Figure 9. An isothiocyanate derivative of deferoxamine (DFO) (DFO-Bz-NCS, Macrocyclics, Plano, TX) was conjugated to the amine groups on MN to form a thiourea bond (12, 13). MN-anti-miR10b (5 mg / mL) was dispersed in 0.1 M NaHCO3 (containing 0.9% NaCl, pH 8.9) and reacted with a 5-fold molar excess of DFO-Bz-NCS (DFO-NCS, 1 mg / mL in DMSO). The mixture was placed on a rocker at 37 °C for 2 h, and the conjugation reaction was terminated by the addition of 1 M Tris (final Tris concentration: 15 mM). 89 Characterization of Zr-MN-anti-miR10b was performed using the MN-anti-miR10b and nat The same steps were followed to characterize Cu-MN-anti-miR10b. For example, to quantify the number of DFOs per MN, the number of amines per MN was subtracted from the number of amines per MN after conjugation with DFO. Figure 10 shows additional exemplary chelators that may be suitable for the synthesis of therapeutic magnetic radiolabeled nanoparticles described herein.

[0164] Cellular uptake nat The cellular uptake of Cu-MN-anti-miR10b was compared with that of MN-anti-miR10b and parental MN. 4T1-luc cells were seeded in 12-well plates. natCells were incubated with Cu-MN-anti-miR10b, MN-anti-miR10b, and MN for 24 hours at 37°C. After washing with DPBS, cells were lysed (Cell lysis buffer, Sigma-Aldrich, St. Louis, MO) and analyzed by ICP-MS to determine iron concentration. Protein concentration was measured by BCA assay (Sigma-Aldrich, St. Louis, MO). Nanoparticle cellular uptake was normalized to total protein.

[0165] Real-time quantitative reverse transcription-PCR Compared to unlabeled MN-anti-miR10b nat To assess target association by Cu-MN-anti-miR10b, 4T1-luc cells were cultured in 1000 x g of 4T1-luc cells. nat Cells were incubated with Cu-MN-anti-miR10b, MN-anti-miR10b, and MN for 48 hours at 37°C. MicroRNA-enriched fractions were collected from cell lysates using the miRNeasy Mini Kit according to the manufacturer's protocol (Qiagen Inc., Hilden, Germany). Relative expression of miR-10b was determined by real-time quantitative reverse transcription PCR (qRT-PCR; TaqMan protocol) and normalized to the internal housekeeping gene SNORD44. TaqMan analysis was performed using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Primers (Hs-miR-10b-3 miScript Primer, Hs-SNORD44-11 miScript Primer) and an assay kit (miScript PCR Starter Kit, Qiagen, Hilden, Germany) were used.

[0166] [Example 6] 64 Biodistribution of Cu-MN-anti-miR10b Next, a total of 13 mice bearing luciferase-expressing metastatic breast adenocarcinoma (4T1-luc2) were used. 64The biodistribution of Cu-MN-anti-miR10b was assessed by PET-MRI and ex vivo gamma counting. 4T1-luc2 cells express luciferase, which can be detected by non-invasive bioluminescence imaging (BLI). Two different concentrations of Cu-MN-anti-miR10b were used. 64 We investigated Cu-MN-anti-miR10b: 1) at tracer-level doses, called microdoses; 64 Cu-MN-anti-miR10b (1 mg Fe / kg, n = 6), and 2) co-injected with MN-anti-miR10b, referred to as macrodose. 64 Therapeutic dose of Cu-MN-anti-miR10b (15 mg Fe / kg, n = 7) was administered. Mice were scanned by PET-MRI at different time points. After in vivo imaging, mice were sacrificed at 24 h pi (n = 3 in the microdose group and n = 4 in the macrodose group) and 48 h pi (n = 3 in each group) for ex vivo biodistribution assessment (Figures 11A-11D). Time-activity curves of the liver, kidney, and heart obtained from PET images (Figures 12A-12C) show that most of the injected dose was rapidly taken up by the liver. This is in line with previously reported studies (Briley-Saebo et al., 2004; Estevanato et al., 2012; Schlachter et al., 2011).

[0167] This is also supported by ex vivo biodistribution analysis, which showed that most of the injected dose was present in the liver and spleen, with %ID / g values ​​in the liver of 61.2 ± 6.5 (24 h, microdose), 53.4 ± 7.1 (24 h, macrodose), 54.3 ± 5.5 (48 h, microdose), and 32.1 ± 13.0 (48 h, macrodose) (Figures 11A and 11B, see inset). %ID / g values ​​lower than 4 were measured in all other harvested organs and tissues. 64Because Cu-MN-anti-miR10b accumulates in metastatic lesions, higher %ID / g values ​​were observed in organs with metastatic lesions, such as lymph nodes, brain, bone, and lung (Figures 11A, 11B, 13A, and 13B, # indicates organ with metastatic lesions). Lymph node metastasis was greater in the macrodose group, explaining the higher ID / g values ​​obtained compared with the microdose group. At 24 and 48 hours after injection, comparable biodistribution was observed between the microdose and macrodose groups (Figures 11A, 11B, 13A, and 13B; note the presence of metastatic lesions in lymph nodes, brain, lung, and bone). This is also reflected in the strong correlation, with a slope close to 1, observed between the %ID / g obtained after microdosing and the %ID / g obtained after macrodosing at 24 and 48 hours pi in nonmetastatic organs, with Pearson coefficients of 0.91 (p<0.0001, slope=1.38) and 0.78 (p=0.004, slope=1.05), respectively (Figures 11C and 11D).

[0168] Animal models and 64 Administration of Cu-MN-anti-miR10b Eight-week-old female Balb / c mice (The Jackson Laboratory; Bar Harbor, ME) were transfected with the 4T1-Red-Fluc cell line (0.5 × 10 6 The cells were orthotopically implanted under the right upper third mammary fat pad. The cells express luciferase and can be detected by non-invasive bioluminescence imaging (BLI) for corresponding analysis of tumor burden. All animals were scanned twice a week with BLI to track the formation of metastases. Two weeks after cell inoculation, the mice 64 Cu-MN-anti-miR10b was injected intravenously. For microdose studies, the preparation was as described above. 64 Cu-MN-anti-miR10b was injected at a dose of 20 μg Fe, 118-190 μCi per mouse, n=6. For vehicle-added macrodose studies, 64Cu-MN-anti-miR10b was mixed with NODAGA-MN-anti-miR10b and injected at a dose of 300 μg Fe, 127–135 μCi per mouse, n = 7. Aliquots of the injected dose were analyzed for %ID / g calculations. After PET-MR imaging, mice were sacrificed at 24 h post-injection (n = 3 in the microdose group and n = 4 in the macrodose group) and 48 h post-injection (n = 3 in each group) for ex vivo biodistribution analysis.

[0169] Bioluminescence Optical Imaging (BLI) BLI was used to identify metastatic lesions. Imaging was performed using an IVIS Spectrum imaging system (Perkin Elmer, Hopkinton, MA). Anesthetized mice were intraperitoneally injected with D-luciferin potassium salt (200 mL of 15 mg / mL; Perkin Elmer, Hopkinton, MA) in DPBS 12 minutes before image acquisition. Total intensity (photons / second / cm) across the whole body was measured using identical image acquisition settings (time, approximately 0.5–60 seconds; F-stop, 2; binning, medium) and the same ROI. 2 / sr). BLI was performed for approximately 6–15 min to obtain maximum brightness. All images were processed using Living Image Software (ver 4.5, IVIS Spectrum, Perkin Elmer, Hopkinton, MA). Total brightness from the bioluminescence readings was used for signal quantification.

[0170] PET-MR imaging Mice were imaged in a 4.7 Tesla MRI scanner equipped with a PET insert (Bruker, Billerica MA). Mice were anesthetized with 1-2% isoflurane in medical air. Mice were kept warm using an air heater system, and body temperature and respiratory rate were monitored with a physiological monitoring system (SA Instruments Inc., Stony Brook NY) throughout the imaging session. 64Dynamic PET acquisition was performed continuously for 1 hour after Cu-MN-anti-miR10b injection. Mice were then returned to their cages and imaged again for 30, 30, 60, and 60 minutes at 2, 4, 24, and 48 hours post-injection, respectively. 64 Twenty-four hours after injection of Cu-MN-anti-miR10b, mice were scanned for 60 minutes. For ex vivo imaging, organs were placed in plastic holders and scanned for 15 minutes.

[0171] Anatomical MR images were acquired simultaneously with PET imaging using a T1-weighted 3D FLASH (Fast Low Angle Shot) sequence with the following parameters: echo time (TE) = 3 ms, repetition time (TR) = 20 ms, and image resolution = 0.25 × 0.25 × 0.5 mm. 3 / voxel, flip angle = 12 degrees.

[0172] Analyze PET-MR imaging data 64 The biodistribution and clearance of Cu-MN-anti-miR10b were estimated using the AMIDE software package (Loening and Gambhir, 2003). Regions of interest (ROIs) were drawn on MR images of major organs, such as the heart, liver, and kidneys, and used to quantify radioactivity in each PET frame in metastatic lesions and corresponding non-metastatic tissues. 64 Cu-MN-anti-miR10b uptake was quantified using ROIs on metastatic bones and lymph nodes identified by BLI, as well as on their non-metastatic contralateral tissues. Results were expressed as percent injected dose per cubic centimeter of tissue (%ID / cc).

[0173] Ex vivo biodistribution Animals were sacrificed 24 and 48 hours after injection. The following organs and tissues were collected: lymph nodes, blood, urine, kidneys, liver, spleen, pancreas, heart, lungs, brain, femur, bladder, and muscle. After excision and ex vivo scanning, organs were weighed, and counts for each organ were determined and attenuation corrected using a gamma counter (Wizard, Perkin Elmer).

[0174] statistical analysis Data were expressed as mean ± SD. Statistical comparisons were performed using two-tailed t-tests using GraphPad Prism software. A p value of less than 0.05 was considered statistically significant.

[0175] [Example 7] In tumors and metastases 64 PET-MRI of Cu-MN-anti-miR10b accumulation Two weeks after orthotopic tumor cell implantation, once metastatic lesions were identified by BLI, mice were 64 Cu-MN-anti-miR10b was injected intravenously. Metastatic organs were identified by in vivo and ex vivo BLI. After injection of a microdose (20 μg Fe, 118–190 μCi per mouse, n=6) without carrier or a macrodose (300 μg Fe, 127–135 μCi per mouse, n=7) with carrier as defined above, metastatic lesions were identified. 64 Cu-MN-anti-miR10b uptake was assessed by PET-MRI. After in vivo PET-MR imaging, mice were sacrificed at 24 and 48 hours pi for ex vivo PET-MR imaging.

[0176] Similar to the biodistribution results, the liver and spleen showed very high PET signals, indicating hepatic clearance. Renal clearance was the other major clearance pathway, as indicated by high PET signals in the kidneys and urine (Figures 11A and 11B). Metastatic lesions in the bone and lymph nodes, in part due to their spatial distance from the liver and spleen, could be identified by in vivo PET-MRI (Figure 14A). 64 Time-activity curves from metastatic and non-metastatic bone after microdose injection of Cu-MN-anti-miR10b showed higher uptake by metastatic foci (FIG. 15). 64 Twenty-four hours after microdose or macrodose injection of Cu-MN-anti-miR10b, metastatic lymph nodes and bones identified by BLI exhibited significantly higher %ID / cc than corresponding organs without metastases (Figure 14B).

[0177] 64 BLI images of bone metastatic lesions after microdose injection of Cu-MN-anti-miR10b are shown in Figure 14C. 64 Cu-MN-anti-miR10b uptake was further confirmed by ex vivo PET-MRI (Figure 14C). Metastatic bones and lymph nodes could be identified by in vivo BLI. These metastatic lesions showed higher ex vivo PET signals than non-metastatic lesions.

[0178] Consistent with ex vivo biodistribution and in vivo PET-MRI, ex vivo imaging showed that activity associated with the resected liver and spleen was highest in both macro- and micro-dosed studies. High activity was also seen in tumor-colonized organs, such as lymph nodes, bone, and lung (Figure 14D).

[0179] Together, these observations support the methodology for radiolabeling and imaging of MN-anti-miR10b and other similar nanotherapeutics. These findings demonstrate the feasibility of clinical PET-MRI of therapeutic drug accumulation in metastatic lesions as an important step on the path to technology transfer of related therapeutics.

[0180] Consideration MicroRNA-10b was previously identified as a master regulator of metastatic tumor cell viability, and a therapeutic miR-10b inhibitor, MN-anti-miR10b, was designed for the treatment of metastatic cancer (Ma et al., 2007; Yigit et al., 2013; Yoo et al., 2015). MN-anti-miR10b was shown to induce complete and durable regression of regional lymph nodes and distant metastases in a breast cancer model without evidence of systemic toxicity (Yoo et al., 2015; Yoo et al., 2017b).

[0181] In this study, an important technology transfer experiment was performed that could pave the way for the application of MN-anti-miR10b in patients with advanced metastatic cancer. 64 We developed Cu-MN-anti-miR10b. This therapeutic agent was shown to maintain effective target binding by radiolabeling without affecting its physicochemical properties or cellular uptake in vitro, and by completely inhibiting miR10b in tumor cells. PET-MRI microdosing then adequately reflected the biodistribution of the therapeutic dose of the agent. 64 Based on the uptake of Cu-MN-anti-miR10b, it was shown to be effective in highlighting metastatic tissues.

[0182] The tools and methods described herein will enable the demonstration of therapeutic drug delivery to clinical metastases and the characterization of drug biodistribution in cancer patients. Indeed, one of the major challenges facing the development of similar therapeutic drugs is effective delivery to target organs. In the case of drug delivery to metastases, complicating factors include the large size of the lesions compared to animal models, the heterogeneity of human disease, and differences in drug pharmacokinetics due to hemodynamic differences between species. Based on these differences, it is not possible to directly extrapolate preclinical biodistribution and efficacy data to demonstrate the successful clinical implementation of a therapeutic agent.

[0183] Therefore, the ability to conduct microdose PET studies in patients under investigational new drug application protocols is an important step toward clinical approval. Because PET technology is sensitive enough to measure radiolabeled drug concentrations approaching the subpicomolar range, typically as little as 1 microgram of radiolabeled drug is sufficient for proposed human PET studies. This feature represents a significant advantage in the early stages of drug development. Because the radiolabeled drug mass is too small to be effective, first-in-human approval from the U.S. Food and Drug Administration can be obtained more quickly and with more limited preclinical safety and toxicity documentation than is required for therapeutic drugs.

[0184] Surprisingly, this study observed identical behavior between the microdose and the therapeutic dose, supporting the rationale for proceeding with microdose testing in patients. The implications of this exploratory imaging study are threefold. First, it will establish that MN-anti-miR10b, which is highly effective in mice, can also accumulate in human metastatic lesions. This significantly reduces the risk of clinical development of therapeutics by demonstrating that drug delivery is feasible. The failure of nanotherapeutics was due to poor delivery and the fact that human tumors are larger than mouse tumors, resulting in different surface area-to-volume ratios. Second, the proposed study will clarify the pharmacokinetic behavior of MN-anti-miR10b, which may enable the establishment of therapeutic dosing during treatment. Third, if MN-anti-miR10b reaches clinical trials, the radiolabeled drug could be used to select patients for treatment based on which patients' metastatic lesions accumulate the therapeutic drug.

[0185] 64 The successful synthesis and testing of Cu-MN-anti-miR10b is significant because it sets a precedent not only for iron oxide delivery platforms like those exemplified herein, but also for testing similar nanotherapeutics based on other nanoparticles that show the potential to provide multimodal treatments. For example, copper-based nanomedicines, such as copper-cysteamine, could be employed to combine RNA-based targeted therapy with copper-cysteamine-based X-ray-induced photodynamic therapy, which has shown promise in cancer (Li et al., 2010; Ma et al., 2014; Shrestha et al., 2019).

[0186] With particular reference to RNA-based therapeutics, the majority of these agents rely on delivery vehicles, often including lipid nanoparticles (e.g., Alnylam's Onpattro, MedImmune's MEDI1191, and AstraZeneca's AZD8601) or GalNAc (e.g., Alnylam's Givlaari, Novartis's Inclisiran, etc.). In these cases, employing relevant radiolabeling and imaging protocols leading up to clinical trials can not only mitigate clinical development risks by demonstrating successful delivery, but may also provide further insight into target engagement as a function of dose, schedule, or agent design.

[0187] The value of clinical microdose imaging studies is believed to be in answering one of the most important questions on the path to drug development: delivery to target organ sites, without the associated costs of conducting full clinical trials. Overall, the data presented herein demonstrate the efficacy of NODAGA and radioactive 64 By introducing Cu, we demonstrate the successful development of radiolabeled MN-anti-miR10b therapeutic agents. 64 The biodistribution of Cu-MN-anti-miR10b was investigated after microdose injection, demonstrating comparable biodistribution in all organs to that of a therapeutic macrodose. The radiolabeling and imaging protocol described herein can advance the clinical development of similar nanotherapeutics by elucidating the pharmacokinetic behavior of the agent, mitigating future clinical trial risks, and aiding in patient selection for treatment based on which patients' metastatic foci accumulate the therapeutic agent.

[0188] Other embodiments While the present invention has been described in conjunction with its detailed description, it is to be understood that the foregoing description is intended to illustrate, but not to limit, the scope of the invention as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

1. 1. A therapeutic nanoparticle comprising: radioactive label; a chelator covalently attached to the therapeutic nanoparticle and the radiolabel; and a nucleic acid molecule covalently attached to said therapeutic nanoparticle, having a diameter of about 10 nanometers (nm) to about 30 nm; Magnetic therapeutic nanoparticles.

2. The therapeutic nanoparticle of claim 1 , wherein the chelator is covalently attached to the therapeutic nanoparticle via a chemical moiety that contains a secondary amine.

3. the chelator comprises 1,4,7-triazacyclononane, 1-glutarate-4,7-acetic acid (NODAGA); and / or The therapeutic nanoparticle of claim 1 or 2, wherein the chelator comprises DOTA, DOTA-GA, p-SCN-Bn-DOTA, CB-TE2A, CB-TE1A1P, AAZTA, MeCOSar, p-SCN-Bn-NOTA, NOTA, HBED-CC, THP, MAS 3 , DFO or any combination thereof.

4. the radiolabel comprises copper-64 (Cu-64); and / or 4. The therapeutic nanoparticle of any one of claims 1 to 3, wherein the radiolabel comprises copper-67 (Cu-67), yttrium-90 (Y-90), terbium-161 (Tb-161), lutetium-177 (Lu-177), bismuth-231 (Bi-213), lead-212 (Pb-212), actinium-225 (Ac-225), zirconium-89 (Zr), or any combination thereof.

5. the nucleic acid molecule comprises at least one modified nucleotide, Optionally, said at least one modified nucleotide is a locked nucleotide; and / or the nucleic acid molecule is antagomir; Optionally, said antagomir inhibits microRNA-10b (miR-10b); and / or The therapeutic nanoparticle of any one of claims 1 to 4, wherein the nucleic acid molecule is covalently attached to the nanoparticle via a chemical moiety that comprises a disulfide bond.

6. The therapeutic nanoparticle comprises an iron oxide core, and / or the therapeutic nanoparticle further comprises a polymeric coating; Optionally, The therapeutic nanoparticle of any one of claims 1 to 5, wherein the polymer coating comprises dextran.

7. A pharmaceutical composition comprising the therapeutic nanoparticles according to any one of claims 1 to 6.

8. and / or further comprising at least one pharma- ceutically acceptable carrier or diluent; 8. The pharmaceutical composition of claim 7, formulated into a dosage form that is an injection, a tablet, a lyophilized powder, a suspension, or any combination thereof.

9. 1. A pharmaceutical composition for use in a method of reducing cancer cell invasion or metastasis in a subject having cancer, comprising: The pharmaceutical composition comprises a therapeutic nanoparticle according to any one of claims 1 to 6, The pharmaceutical composition, wherein the method comprises administering to a subject having cancer the therapeutic nanoparticles, wherein the therapeutic nanoparticles are administered in an amount sufficient to reduce cancer cell invasion or metastasis in the subject.

10. the therapeutic nanoparticles are administered to the subject at a dose that is less than about 0.014 mg / kg; and / or the metastasis of the cancer cells is from a primary tumor to a lymph node in the subject, or from a lymph node to a secondary tissue in the subject; and / or 10. The pharmaceutical composition of claim 9, wherein the cancer cells are selected from the group consisting of breast cancer cells, colon cancer cells, renal cancer cells, lung cancer cells, skin cancer cells, ovarian cancer cells, pancreatic cancer cells, prostate cancer cells, rectal cancer cells, gastric cancer cells, thyroid cancer cells, and uterine cancer cells.

11. The pharmaceutical composition of any one of claims 7 to 10, further comprising imaging a tissue of the subject to determine the location or number of cancer cells in the subject, or the location of a therapeutic nanoparticle in the subject.

12. 1. A pharmaceutical composition for use in a method of treating metastatic cancer in a lymph node of a subject, comprising: The pharmaceutical composition comprises a therapeutic nanoparticle according to any one of claims 1 to 6, The pharmaceutical composition, wherein the method comprises administering the therapeutic nanoparticles to a lymph node of a subject having metastatic cancer, wherein the therapeutic nanoparticles are administered in an amount sufficient to treat the metastatic cancer in the lymph node of the subject.

13. the metastatic cancer originates from a primary breast cancer, and / or 13. The pharmaceutical composition of claim 12, wherein said administering results in a reduction or stabilization of the size of a metastatic tumor in said subject, or a reduction in the rate of growth of a metastatic tumor in a lymph node.

14. A pharmaceutical composition for use in a method for detecting, diagnosing, and / or monitoring metastatic cancer tissue in a subject, comprising: The pharmaceutical composition comprises a therapeutic nanoparticle according to any one of claims 1 to 6, The method further comprising: administering the therapeutic nanoparticles to the subject having the metastatic cancer tissue; and Imaging the therapeutic nanoparticles. Including, The pharmaceutical composition, wherein the therapeutic nanoparticles are administered in an amount sufficient to image the therapeutic nanoparticles in the subject.

15. 15. The pharmaceutical composition of claim 14, wherein the imaging is performed by magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), computed tomography (CT), or any combination thereof.

16. The therapeutic nanoparticles are administered to the subject in two or more doses, and / or 15. The pharmaceutical composition of any one of claims 9, 12, or 14, wherein the therapeutic nanoparticles are administered to a subject at least once a week.

17. 15. The pharmaceutical composition of any one of claims 9, 12, or 14, wherein the therapeutic nanoparticles are administered to the subject by intravenous, subcutaneous, intraarterial, intramuscular, or intraperitoneal administration.

18. 15. The pharmaceutical composition of any one of claims 9, 12, or 14, wherein the subject is further administered a chemotherapeutic agent.

19. A method for preparing a therapeutic nanoparticle according to any one of claims 1 to 6, said method comprising: Preparing the magnetic nanoparticles; covalently attaching said nucleic acid molecules to said magnetic nanoparticles; covalently attaching the chelator to the magnetic nanoparticles by reacting the magnetic nanoparticles with the chelator at a ratio of about 40 chelator equivalents per magnetic nanoparticle; 64 CuCl 2 to the magnetic nanoparticles; and The above 64 CuCl 2 and purifying the mixture of the solution and the magnetic nanoparticles to obtain therapeutic nanoparticles. A method comprising:

20. and / or wherein covalently attaching the chelator to the magnetic nanoparticles is performed at a temperature of about 0° C. to about 8° C. The method further comprising: further comprising heating the mixture of the 64 CuCl 2 solution and the magnetic nanoparticles at a temperature of about 40° C. to about 65° C.; Optionally, The method of claim 19, wherein the mixture is heated for about 10 minutes to about 30 minutes.